Compositions and methods for immune activation

By using a composition containing lactic acid bacteria and/or acetic acid bacteria with amino acids, peptides, and proteins, the activation of pDC and the production of IFN-α are enhanced, solving the problem of insufficient immune function activation capacity in the prior art and achieving a significant immune function enhancement effect.

CN123124884APending Publication Date: 2026-11-17KIRIN HOLDINGS KK
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202580027891.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-04-19
Filing Date
2025-04-16
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

There is a lack of effective methods in the current technology to enhance immune function activation, especially by combining amino acids, peptides and proteins with bacteria that have immune-activating capabilities to enhance the induction of pDC activation and IFN-α production.

Method used

An immune-activating composition is provided, comprising bacteria with immune-activating capabilities and one or more compounds selected from the group consisting of amino acids, peptides and proteins, for enhancing pDC activation and IFN-α production, specifically including lactic acid bacteria and/or acetic acid bacteria, such as Lactococcus lactis, Weissella asiatica, Bifidobacterium, etc., to enhance immune activation by administration or ingestion of these compositions.

Benefits of technology

It significantly enhanced the activation of pDC and the production of IFN-α, thereby enhancing immune function, especially by increasing the expression of IFN-α, achieving an enhancement effect of more than 1.10 times.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

The present invention discloses an immune-activating composition comprising bacteria with immune-activating capabilities and one or more compounds selected from the group consisting of amino acids, peptides and proteins that enhance the immune-activating capabilities of said bacteria.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to compositions and methods for immune activation. Background Technology

[0002] Immunity is a biological defense mechanism that prevents foreign substances from entering the body and detects and eliminates them, playing a vital role in maintaining health. On the other hand, factors that weaken the immune system, including lack of exercise, overwork, stress, insufficient sleep, smoking, and alcohol consumption, expose individuals to the risk of weakened immune function daily. Therefore, the development of technologies to activate immune function is underway.

[0003] As a technical means, for example, compositions that can activate immune function through the ingestion of drugs and foods have been developed. For instance, Patent Document 1 discloses an interferon (IFN) production inducer containing, as an active ingredient, a culture or treatment of plasmacytoid dendritic cells (pDCs) that can activate interferon (IFN) production, lactic acid bacteria, or the like. Patent Document 2 discloses an immune-activating composition containing, as an active ingredient, lactic acid bacteria with immune-activating activity and an ester conjugate of polyol and saturated fatty acid. Patent Document 3 discloses a method for manufacturing immune-activating lactic acid bacteria without the ester conjugate of polyol and fatty acid, comprising: contacting an immune-activating composition containing the ester conjugate of polyol and fatty acid as an active ingredient with immune-activating lactic acid bacteria, and then removing the immune-activating composition.

[0004] In order to use the composition that can activate immune function as pharmaceuticals and food products where quality control is required, it is necessary to control the composition by enhancing or inhibiting its ability to activate immune function.

[0005] Existing technical documents

[0006] Patent documents

[0007] Patent Document 1: International Publication No. 2012 / 091081

[0008] Patent Document 2: Japanese Patent Application Publication No. 2016-005452

[0009] Patent Document 3: Japanese Patent Application Publication No. 2017-085975 Summary of the Invention

[0010] The object of this invention is to provide a novel composition for immune activation.

[0011] The inventors discovered that one or more compounds selected from the group consisting of specified amino acids, peptides, and proteins can enhance pDC activation induced by specified bacteria with immune-activating capabilities and the associated IFN-α production, thus completing the present invention.

[0012] The present invention provides, for example, the following inventions.

[0013] [1] An immune-activating composition comprising: Bacteria with immune-activating capabilities; and One or more compounds selected from the group consisting of amino acids, peptides, and proteins that enhance the immune activation ability of the aforementioned bacteria.

[0014] [2] An immune activation method, comprising: The administration of a drug to a subject or the ingestion of an immune-activating bacterium by the subject, and one or more compounds selected from the group consisting of amino acids, peptides and proteins that enhance the immune-activating ability of the aforementioned bacteria.

[0015] [3] A method for enhancing immune activation induced by bacteria with immune-activating capabilities, comprising: The administration of a drug to a subject or the ingestion of an immune-activating bacterium by the subject, and one or more compounds selected from the group consisting of amino acids, peptides and proteins that enhance the immune-activating ability of the aforementioned bacteria.

[0016] [4] An immune-activating enhancer induced by bacteria with immune-activating ability, comprising one or more compounds selected from the group consisting of amino acids, peptides and proteins that enhance the immune-activating ability of bacteria with immune-activating ability.

[0017] [5] An enhancer of immune activation induced by bacteria with immune-activating capabilities, comprising: Bacteria with immune-activating capabilities; and One or more compounds selected from the group consisting of amino acids, peptides, and proteins that enhance the immune activation ability of the aforementioned bacteria.

[0018] [6] A composition for immune activation induced by bacteria with immune-activating capabilities, comprising one or more compounds selected from the group consisting of amino acids, peptides and proteins that enhance the immune-activating capabilities of bacteria with immune-activating capabilities.

[0019] [7] The use of bacteria with immune-activating ability and one or more compounds selected from the group consisting of amino acids, peptides and proteins that enhance the immune-activating ability of the above-mentioned bacteria in the manufacture of an immune-activating composition.

[0020] [8] The use of one or more compounds selected from the group consisting of amino acids, peptides and proteins that enhance the immune activation of bacteria with immune activation capabilities in the manufacture of a composition for immune activation induced by the aforementioned bacteria.

[0021] [9] The use of one or more compounds selected from the group consisting of amino acids, peptides and proteins that enhance the immune activation ability of bacteria with immune activation capabilities in the manufacture of an immune-activating composition for administration or intake in combination with the above-mentioned bacteria.

[0022]

[10] The use of bacteria with immune-activating capabilities in the manufacture of an immune-activating composition which is administered or taken in combination with one or more compounds selected from the group consisting of amino acids, peptides and proteins that enhance the immune-activating capabilities of bacteria with immune-activating capabilities.

[0023]

[11] A compound selected from one or more of the group consisting of amino acids, peptides and proteins that enhance the immune activation capacity of bacteria with immune activation capacity, for use in immune activation induced by the aforementioned bacteria.

[0024]

[12] A bacterium, which is an immune-activating bacterium used in a therapeutic method for immune activation, is administered or ingested in combination with one or more compounds selected from the group consisting of amino acids, peptides and proteins that have the immune-activating capacity-enhancing effect of the aforementioned bacterium.

[0025]

[13] A compound selected from one or more of the group consisting of amino acids, peptides and proteins that enhance the immune activation capacity of bacteria with immune activation capacity, for use in a therapeutic method of immune activation, and administered or in combination with bacteria with immune activation capacity.

[0026]

[14] An application in which bacteria with immune-activating capabilities are used in a non-therapeutic method of immune activation, wherein the bacteria are administered or ingested in combination with one or more compounds selected from the group consisting of amino acids, peptides and proteins that enhance the immune-activating capabilities of the bacteria.

[0027]

[15] An application of a compound selected from the group consisting of amino acids, peptides and proteins that enhance the immune activation capacity of bacteria with immune activation capacity in a non-therapeutic method of immune activation, wherein the compound is administered or ingested in combination with bacteria with immune activation capacity.

[0028]

[16] The composition, method, enhancer, application, compound or bacteria according to any one of [1] to

[15] , wherein the bacteria with immune-activating ability are lactic acid bacteria and / or acetic acid bacteria.

[0029]

[17] The composition, method, enhancer, application, compound or bacteria according to

[16] , wherein the lactic acid bacteria are selected from one or more of the genus Lactococcus, genus Weissella, genus Bifidobacterium and genus Lactobacillus.

[0030]

[18] The composition, method, enhancer, application, compound or bacteria according to

[16] , wherein the lactic acid bacteria are selected from one or more of the genus Lactococcus, genus Weissella and genus Bifidobacterium.

[0031]

[19] The composition, method, enhancer, application, compound or bacteria according to

[17] , wherein the above-mentioned Lactococcus spp. is Lactococcus lactis subsp. lactis or Lactococcus curvularis, the above-mentioned Weissella spp. is Weissella enterica, the above-mentioned Bifidobacterium spp. is Bifidobacterium animalis subsp. lactis, and the above-mentioned Lactobacillus spp. is Lactobacillus plantarum.

[0032]

[20] The composition, method, enhancer, application, compound or bacteria according to

[18] , wherein the above-mentioned Lactococcus spp. is Lactococcus lactis subsp. lactis, the above-mentioned Weissella spp. is Weissella enterica, and the above-mentioned Bifidobacterium spp. is Bifidobacterium animalis subsp. lactis.

[0033]

[21] The composition or application according to any one of [1], [6] to

[10] and

[16] to

[20] , wherein the content of the bacteria having immune-activating ability is 0.001% by mass or more and less than 100% by mass relative to the total amount of the immune-activating composition described above.

[0034]

[22] The composition or application according to any one of [1], [6] to

[10] and

[16] to

[21] , wherein the content of the compound is 0.000001% by mass or more and 90.0% by mass or less relative to the total amount of the immune-activating composition described above.

[0035]

[23] The composition, method, enhancer, application, compound or bacteria according to any one of [1] to

[22] , wherein the ratio of the content (mass%) of the above-mentioned immune-activating bacteria to the content (mass%) of the above-mentioned compound (content of one or more compounds selected from the group consisting of amino acids, peptides and proteins) / (content of immune-activating bacteria) is 0.001 or more and 50,000 or less.

[0036]

[24] The composition, method, enhancer, application, compound or bacteria according to any one of [1] to

[23] , wherein the immune activation ability is the ability to induce the production of interferon α in immune cells.

[0037]

[25] The composition, method, enhancer, application, compound or bacteria according to any one of [1] to

[24] , wherein the immune cells are pDCs.

[0038]

[26] The composition, method, enhancer, application, compound or bacteria according to any one of [1] to

[25] , wherein the above-mentioned immune activation enhancement effect is to enhance the above-mentioned induction of interferon α production of immune cells by more than 1.10 times compared with the immune activation composition containing only bacteria with immune activation ability.

[0039]

[27] A composition, method, enhancer, application, compound or bacteria according to any one of [1] to

[26] , wherein the compound is one or more compounds selected from the group consisting of alanine, asparagine, cysteine, glutamine, leucine, proline, threonine, tryptophan, valine, arginine, histidine, lysine, isoleucine, serine, ornithine, cystine, glutathione, imidazole dipeptide, silk peptide, sardine-derived peptide, casein breakdown product, collagen peptide, wheat protein breakdown product, whey protein breakdown product and elastin.

[0040]

[28] The composition, method, enhancer, application, compound or bacteria according to any one of [1] to

[27] , wherein the compound is glutathione.

[0041]

[29] An immune-activating composition comprising adding one or more compounds selected from the group consisting of amino acids, peptides and proteins that enhance the immune-activating ability of the bacteria to bacteria that have immune-activating ability.

[0042]

[30] A method for manufacturing an immune-activating composition, wherein one or more compounds selected from the group consisting of amino acids, peptides and proteins that enhance the immune-activating ability of the bacteria are added to bacteria that have immune-activating ability. Attached Figure Description

[0043] Figure 1 This is a graph showing the evaluation results of the enhancement effect of reduced glutathione on IFN-α production by plasmacytoid dendritic cells (pDCs) induced by Lactococcus lactis subsp. lactis JCM5805.

[0044] Figure 2This is a graph showing the evaluation results of the enhancing effect of reduced glutathione on IFN-α production induced by lactic acid bacteria in pDCs.

[0045] Figure 3 This is a graph showing the evaluation results of the enhancing effect of reduced glutathione on IFN-α production by bifidobacteria-induced pDCs. Detailed Implementation

[0046] The following describes in detail the methods for implementing the present invention. However, the present invention is not limited to the following embodiments.

[0047] According to the present invention, novel compositions for immune activation can be provided.

[0048] The present invention has been described in connection with specific embodiments and various implementations, but those skilled in the art will readily understand that various modifications and applications can be made to the implementations described herein without departing from the spirit and scope of the present invention.

[0049] This application claims priority based on Japanese Patent Application No. 2024-068171 filed with the Japan Patent Office on April 19, 2024, the contents of which are incorporated herein by reference in their entirety.

[0050] In this disclosure, the phrase "selected from one or more of the groups" includes all combinations that can be formed by one or more elements constituting the group. For example, it can be one of the elements constituting the group, or any combination of two, three, four, five, six, seven, eight, nine or more elements constituting the group.

[0051] [Composition for Immune Activation]

[0052] The first embodiment of this disclosure relates to an immune-activating composition. The immune-activating composition contains bacteria with immune-activating capabilities and one or more compounds selected from the group consisting of amino acids, peptides, and proteins that enhance immune-activating capabilities. The immune-activating composition of one embodiment has an immune-activating effect because it contains bacteria with immune-activating capabilities.

[0053] Immune activation refers to the activation of the innate immune system of a cell or organism. It can increase or maintain (reduce suppression) the function of the innate immune system. A mode of immune activation can include immune cell activation, dendritic cell activation, or dendritic cell activation. When immune activation includes dendritic cell activation or when the immune activation is dendritic cell activation, bacteria with immune activation capabilities also possess dendritic cell activation capabilities.

[0054] Dendritic cell activation (dendritic cell activation capacity) can be defined as an increase in the expression of cytokines in dendritic cells compared to a condition where bacteria with immune activation capacity are not administered or ingested. One form of immune activation (immunoactivation capacity) can include plasmacytoid dendritic cell activation (pDC activation capacity), which can be pDC activation, where the bacteria possess pDC activation capacity when the immune activation includes pDC activation or when the immune activation is pDC activation. pDC activation (pDC activation capacity) can be defined as an increase in the expression of cytokines in pDCs compared to a condition where bacteria with immune activation capacity are not administered or ingested.

[0055] Plasmacytoid dendritic cells (pDCs), also known as plasmacytoid dendritic cells, are one of the dendritic cells that constitute the innate immune system. pDCs are the main type I interferon-producing cells in the body. Type I interferons exhibit proliferative inhibitory activity against viruses and other pathogens. Representative type I interferons include interferon-α (IFN-α) and interferon-β (IFN-β), which are believed to have immune-activating effects. As for type II interferons, interferon-λ (IFN-λ) is also considered to have immune-activating effects. Specific examples of pDCs include CAL-1 cells. CAL-1 cells are a human plasmacytoid dendritic cell cancer cell line established from tumor cells in the peripheral blood of a patient (Japanese Patent Application Publication No. 2007-044008), deposited at the Patent and Microbial Collection Center of the Biotechnology Center of the Japan Biotechnology Center (NPMD, Japan) with accession number FERM BP-10914.

[0056] An immune activation mechanism (immune activation capacity), dendritic cell activation mechanism (dendritic cell activation capacity), or pDC activation mechanism (pDC activation capacity) may include at least one IFN production-promoting mechanism (IFN production-promoting capacity) selected from the group consisting of interferon α (IFN-α), interferon β (IFN-β), and interferon λ (IFN-λ), may include interferon α (IFN-α) production-promoting mechanism (IFN-α production-promoting capacity), and may be an IFN-α production-promoting mechanism (IFN-α production-promoting capacity).

[0057] Whether the immune-activating composition of one embodiment has an immune-activating effect can be appropriately determined. For example, when immune cells are cultured in the presence of the immune-activating composition of one embodiment, if the immune cell function is enhanced compared to when immune cells are cultured in the absence of the composition, it is determined that it has an immune-activating effect. Furthermore, when immune cells are cultured in the presence of the immune-activating composition of one embodiment and a substance that reduces immune cell function, if the immune cell function is maintained (reduced inhibition) compared to when immune cells are cultured in the absence of the composition and in the presence of the substance that reduces immune cell function, it is determined that it has an immune-activating effect. Immune cell function can be evaluated, for example, by indicators such as activation marker molecules (proteins, etc.) indicating that immune cells are in an activated state, or by indicators such as molecules (proteins, etc.; for example, IFN, etc.) produced when immune cells are in an activated state.

[0058] As a more detailed example, whether the immune-activating composition of one embodiment has an immune-activating effect can be confirmed by measuring the IFN-α concentration according to steps (i) to (iv) below.

[0059] (i) Mouse-derived bone marrow cells, after red blood cells were removed, were processed at a rate of 1 × 10⁻⁶. 6 Cell suspensions were prepared by suspending cells / mL in RPMI medium prepared in such a manner that each component described in the <Composition of Culture Medium> below reaches its respective final concentration described in the <Composition of Culture Medium> below.

[0060] <Composition of the culture medium>

[0061] ·10% by volume FBS

[0062] 100 U / mL penicillin / streptomycin

[0063] 1mM Sodium Pyruvate

[0064] ·2.5mM HEPES

[0065] • 1% by mass of non-essential amino acids (NEAA) for MEM

[0066] 50 μM β-mercaptoethanol

[0067] 100ng / mL Flt-3L

[0068] (ii) Inoculate 1 mL of each of the prepared cell suspensions and incubate them in a CO2 incubator at 37°C and 5% CO2 for 1 week to induce pDC.

[0069] (iii) The induced bone marrow cells containing pDCs were injected at a rate of 2 × 10⁻⁶. 5 The bacteria were suspended at a concentration of 1 mg / mL and inoculated into each well of a 96-well plate with 200 μL of the bacterial composition. 2 μL of the bacterial composition was then added to each well, and the concentration was adjusted to 1 mg / mL with PBS.

[0070] (iv) After 24 hours, the culture supernatant was recovered, and the IFN-α concentration was determined by ELISA using an IFN-α assay kit.

[0071] In this specification, "bacteria with immune-activating ability" refers to bacteria capable of activating (activating) immune cells. "Immune-activating ability" simply means the ability to activate immune cells; for example, it can be the ability to induce IFN in immune cells, the ability to induce at least one or more IFNs selected from the group consisting of IFN-α, IFN-β, and IFN-λ in immune cells, or the ability to induce IFN-α in immune cells. "Bacteria with immune-activating ability" can be either live or dead bacterial cells, and can be fragments of live or dead bacterial cells, freeze-dried live or dead bacterial cells, fragments of the freeze-dried cells, culture medium, culture medium extracts, etc., or processed products of these. Here, processed products include, for example, substances obtained by enzymatic treatment, heat treatment, etc., or substances obtained by ethanol precipitation and recovery of substances obtained by treating such substances. "Bacteria with immune-activating ability" is preferably dead bacterial cells, more preferably fragments of dead bacterial cells, freeze-dried cells, or substances obtained by treating the fragments of the freeze-dried cells by heat treatment (heated dead bacterial cells). When "bacteria with immune activation capabilities" are dead bacteria, the bacteria can be manufactured as follows: for example, the live bacteria can be killed by heat treatment, pressure treatment, high-pressure steam treatment, electromagnetic wave treatment, electron beam treatment, radiation treatment, ultraviolet treatment, alcohol treatment or water electrolysis treatment, etc., and then dried as needed by freeze drying, spray drying, drum drying, hot air drying or vacuum drying.

[0072] Regarding whether the bacteria in this embodiment possess immune-activating ability, there is no particular limitation. When immune cells are cultured in the presence of bacteria with immune-activating ability, if the immune cell function is enhanced compared to when immune cells are cultured in the absence of such bacteria, it can be determined that they have an immune-activating effect. As a more detailed example, whether the bacteria in this embodiment possess immune-activating ability can be confirmed by measuring the IFN-α concentration according to steps (i) to (iv) described above.

[0073] Whether the bacteria of this embodiment possesses immune-activating ability can be expressed by the following indicator: a final concentration of pDC of 2 × 10⁻⁶ obtained by culturing the bacteria at a final concentration of 10 μg / mL with cell culture medium recovered from mouse bone marrow and containing 100 ng / mL Flt3-L for 7 days. 5 Bone marrow cells per mL are co-cultured for 24 hours to produce IFN-α at a concentration of 30 pg / mL or higher, preferably 50 pg / mL or higher, more preferably 60 pg / mL or higher, more preferably 70 pg / mL or higher, more preferably 80 pg / mL or higher, more preferably 90 pg / mL or higher, more preferably 100 pg / mL or higher, more preferably 150 pg / mL or higher, more preferably 200 pg / mL or higher, more preferably 250 pg / mL or higher, more preferably 300 pg / mL or higher, more preferably 400 pg / mL or higher, more preferably 500 pg / mL or higher, more preferably 600 pg / mL or higher, more preferably 700 pg / mL or higher, and particularly preferably 800 pg / mL or higher.

[0074] The bacteria used in this embodiment are not particularly limited and can be bacteria harmless to humans. One type of bacteria can be Gram-positive or Gram-negative bacteria. The bacteria in this embodiment can be lactic acid bacteria and / or acetic acid bacteria, particularly lactic acid bacteria. The immune-activating bacteria in this embodiment can be a single bacterium or a mixture of two or more bacteria; for example, it can be one or more lactic acid bacteria, one or more acetic acid bacteria, or a mixture of one or more lactic acid bacteria and one or more acetic acid bacteria.

[0075] Lactic acid bacteria are bacteria that produce lactic acid as a metabolite. Examples of lactic acid bacteria include *Oenococcus*, *Bifidobacterium*, *Weissella*, *Tetragenococcus*, *Lactococcus*, *Leuconostoc*, *Pediococcus*, *Streptococcus*, *Enterococcus*, *Lactobacillus*, *Bacillus*, and *Heyndrickxia* (which is classified as a *Bacillus* species).

[0076] It should be noted that the *Lactobacillus* genus in this invention includes bacteria that were classified as *Lactobacillus* before the reclassification of the *Lactobacillus* genus. For example, this includes bacteria newly classified as *Acetilactobacillus*, *Agrilactobacillus*, *Amylolactobacillus*, *Apilactobacillus*, *Bombilactobacillus*, *Companilactobacillus*, *Dellaglioa*, *Fructilactobacillus*, *Furfurilactobacillus*, *Holzapfelia*, *Lacticaseibacillus*, *Lactiplantibacillus*, and others following the reclassification of *Lactobacillus*. Bacteria belonging to the genera *Lapidilactobacillus*, *Latilactobacillus*, *Lentilactobacillus*, *Levilactobacillus*, *Ligilactobacillus*, *Limosilactobacillus*, *Liquorilactobacillus*, *Loigolactobacillus*, *Paralactobacillus*, *Paucilactobacillus*, *Schleiferilactobacillus*, and *Secundilactobacillus*.

[0077] Among the aforementioned bacteria, the preferred species are *Oenococcus*, *Bifidobacterium*, *Lentilactobacillus*, *Weissella*, *Tetragenococcus*, *Lactococcus*, *Leuconostoc*, *Pediococcus*, and *Enterococcus*. The bacteria include bacteria of the genus *Lactobacillus*, *Lactiplantibacillus*, *Lacticaseibacillus*, and *Limosilactobacillus*, more preferably *Lactococcus*, *Weissella*, *Bifidobacterium*, and *Lactobacillus*.

[0078] The term "Oenococcus" is not specifically limited to the aforementioned species; examples include *Oenococcus oeni*. Specific examples of *Oenococcus* include *Oenococcus oeni* JCM6125.

[0079] The term "Bifidobacterium" is not specifically limited to these species; examples include *Bifidobacterium animalis* subsp. *lactis* and *Bifidobacterium longum* subsp. *infantis*. Specific examples of *Bifidobacterium* include *Bifidobacterium animalis* subsp. *lactis* JCM10602, *Bifidobacterium longum* subsp. *infantis* JCM1222, and *Bifidobacterium longum* subsp. *BB536*.

[0080] The term "Weissella" as used is not specifically limited, and examples include *Weissella paramesenteroides* and *Weissella viridescens*. Specific examples of *Weissella* include *Weissella paramesenteroides* JCM9890 and *Weissella viridescens* JCM1174.

[0081] The term "tetracoccus" is not specifically limited to these species; examples include Tetragenococcus halophilus. Specific examples of Tetracoccus include Tetragenococcus NRIC0098 and Tetragenococcus halophilus No. 1.

[0082] The term "Lactococcus" is not specifically limited to any of the aforementioned species; examples include *Lactococcus lactis*, *Lactococcus lactis* subsp. *lactis*, *Lactococcus garvieae*, *Lactococcus lactis* subsp. *cremoris*, *Lactococcus lactis* subsp. *hordniae*, *Lactococcus curvatus*, and *Lactococcus plantarum*.

[0083] Specific examples of the aforementioned *Lactococcus* species include *Lactococcus lactis* subsp. *lactococcus* JCM5805 (hereinafter sometimes referred to as JCM5805), *Lactococcus lactis* subsp. *lactococcus* NBRC12007, *Lactococcus lactis* subsp. *lactococcus* NRIC1150, *Lactococcus lactis* subsp. *lactococcus* subsp. *lactococcus* JCM20101, *Lactococcus lactis* subsp. *lactococcus* JCM7638, *Lactococcus lactis* subsp. *lactococcus* subsp. *lactococcus* ATCC 7963, *Lactococcus lactis* subsp. *lactococcus* subsp. *lactococcus* ATCC 7962, *Lactococcus lactis* subsp. *lactococcus* subsp. *lactococcus* subsp. *lactococcus* ATCC 29146, *Lactococcus lactis* subsp. *lactococcus* subsp. *lactococcus* ATCC 27861, *Lactococcus lactis* subsp. *lactococcus* subsp. *lactococcus* ATCC 19435, *Lactococcus lactis* subsp. *lactococcus* subsp. *lactococcus* ATCC 15577, *Lactococcus lactis* subsp. *lactococcus* subsp. *lactococcus* ATCC 15346, *Lactococcus lactis* subsp. *lactococcus* subsp. *lactococcus* ATCC 13675, and so on. 12929, *Lactococcus lactis* subsp. *milk* ATCC 11955, *Lactococcus lactis* subsp. *milk* ATCC 11454, *Lactococcus lactis* subsp. *milk* ATCC 11007, *Lactococcus gasseri* NBRC 100934, *Lactococcus lactis* subsp. *milk fat* JCM 16167, *Lactococcus lactis* subsp. *milk fat* NBRC 100676, *Lactococcus lactis* subsp. *Hosne* JCM 1180, *Lactococcus lactis* subsp. *Hosne* JCM 11040, *Lactococcus curvularis* JCM 1096, and *Lactococcus plantarum* JCM 11056, etc.

[0084] The term "Leuconostoc" as used is not specifically limited, and examples include *Leuconostoc carnosum* and *Leuconostoc lactis*. Specific examples of *Leuconostoc* include *Leuconostoc carnosum* JCM9695 and *Leuconostoc lactis* NBRC12455.

[0085] The term "Pediococcus" as used is not specifically limited, and examples include *Pediococcus acidilactici*, *Pediococcus pentosaceus*, *Pediococcus cellicola*, *Pediococcus claussenii*, *Pediococcus damnosus*, *Pediococcus ethanolidurans*, *Pediococcus inopinatus*, *Pediococcus parvulus*, and *Pediococcus stilesii*. Specific examples of *Pediococcus* include *Pediococcus acidilactici* JCM8797, *Pediococcus acidilactici* K15, and *Pediococcus stilesii* JCM5886.

[0086] The term "Streptococcus" is not specifically limited to any particular species; examples include *Streptococcus thermophilus*. Specific examples of the genus *Pediococcus* include *Streptococcus thermophilus* SBC8781.

[0087] The term "Enterococcus" is not specifically limited to these species; examples include *Enterococcus alcedinis* and *Enterococcus faecalis*. Specific examples of *Enterococcus* include *Enterococcus faecalis* EC-12.

[0088] The *Lactobacillus* species mentioned above are not specifically limited to any particular species, but may include, for example, *Lactobacillus paracasei*, *Lactobacillus paracasei subsp. paracasei*, *Lactobacillus casei subsp. paracasei*, *Lactobacillus delbrueckii*, *Lactobacillus acidophilus*, *Lactobacillus casei*, *Lactobacillus fructivorans*, *Lactobacillus hilgardii*, *Lactobacillus rhamnosus*, *Lactobacillus casei*, *Lactobacillus gasseri*, *Lactobacillus acidophilus*, and *Lactobacillus bulgaricus*. Lactobacillus bulgaricus, Lactobacillus parakefiri, Lentilactobacillus parakefiri, Lactobacillus plantarum, Lactiplantibacillus plantarum, Lactobacillus plantarum subsp. plantarum, Lactiplantibacillus plantarum subsp. plantarum, Lactobacillus pentosus, Lactiplantibacillus pentosus, Lactobacillus helveticus, and Limosilactobacillus reuteri subsp.Lactobacillus reuteri, Lactobacillus crispatus, Lactobacillus paraplantarum, Lactobacillus paraplantarum, and Lactobacillus johnsonii, among others.

[0089] Specific examples of Lactobacillus species include: *Lactobacillus paracasei* KW3110, *Lactobacillus paracasei* MCC1849, *Lactobacillus paracasei* K71, *Lactobacillus paracasei* K-2, *Lactobacillus rhamnosus* GG, *Lactobacillus rhamnosus* CRL1505, *Lactobacillus gasseri* SBT2055, *Lactobacillus acidophilus* L-92, *Lactobacillus casei* subsp. casei 327, *Lactobacillus casei* (referred to as *Lactobacillus casei* in the new classification) *shirota*, *Lactobacillus bulgaricus* OLL1073R-1, and *Lactobacillus parakefeldiana* (referred to as *Slow-growing parakefeldiana* in the new classification). Lactobacillus johnsonii (JCM8573), Lactobacillus plantarum (Lactobacillus plantarum in the new classification) L-137, Lactobacillus pentosaccharide (Lactobacillus pentosaccharide in the new classification) ONRICb0240, Lactobacillus plantarum-like (Lactobacillus plantarum in the new classification) JCM1149, Lactobacillus acidophilus JCM1021, Lactobacillus acidophilus JCM1132, Lactobacillus helveticus JCM1003, Lactobacillus reuteri subsp. reuteri JCM1112, Lactobacillus curvaturei JCM1185, and Lactobacillus johnsonii JCM2012, etc.

[0090] The term "Bacillus" is not specifically limited to these examples; for instance, *Bacillus coagulans* can be cited. Specific examples of *Bacillus* strains include *Bacillus coagulans* SANK70258.

[0091] As for the genus *Heyndrickxia*, there is no particular limitation; examples include *Heyndrickxia coagulans* (also known as *Bacillus coagulans*). Specific examples of *Heyndrickxia* include *Heyndrickxia coagulans* (SANK 70258) and *Heyndrickxia coagulans* (BC99).

[0092] Acetic acid bacteria are bacteria that produce acetic acid as a metabolite. There is no particular limitation on the type of acetic acid bacteria; examples include bacteria of the genus *Gluconacetobacter*, *Acetobacter*, and *Gluconobacter*, with *Gluconacetobacter* being the preferred example, *Gluconacetobacter* being a more preferred example, and *Gluconacetobacter hannifolia* GK-1 being an even more preferred example.

[0093] In addition to the above, lactic acid bacteria can also be Akkermansia, Bacteroides, Blautia, Clostridium, Collinsella, Faecalibacterium, Faecalicatena, Lacrimispora, Paeniclostridium, Parabacteroides, or Roseburia.

[0094] Specific examples of Akkermansia include Akkermansia myxophilus JCM30893.

[0095] Specific examples of Bacteroides include Bacteroides faecalis JCM9498T, Bacteroides fragilis JCM11019T, Bacteroides fragilis JCM11017, Bacteroides fragilis JCM17586, Bacteroides fragilis JCM17587, Bacteroides ovatus JCM5824T, Bacteroides polymorpha ATCC29148T, Bacteroides polymorpha ATCC29741, Bacteroides polymorpha ATCC12290, Bacteroides monomorpha JCM5828T, Bacteroides monomorpha JCM13286, Bacteroides monomorpha JCM13287, and Bacteroides monomorpha JCM13288.

[0096] Specific examples of *Blautia* species include *Blautia acetogenes* JCM34803T, *Blautia ammonialytica* JCM34802T, *Blautia argus* JCM31394T, *Blautia mouse cecum* JCM34498T, *Blautia sclerotiorum* JCM1395T, *Blautia fecal* JCM17205T, and *Blautia glucosinolates*. The following bacteria are listed: *Brutella glucerasea* JCM17039T, *Brutella hannivarum* JCM14655, *Brutella hannivarum* JCM35484, *Brutella humanis* JCM32276T, *Brutella hydrophila* JCM31266, *Brutella baijiu* JCM34225T, *Brutella rhudiella* JCM17040T, *Brutella ovalis* JCM31340, *Brutella prolongata* JCM1471T, *Brutella pseudococcus* JCM35243T, *Brutella schenckii* JCM14657T, *Brutella westermani* JCM31267, and *Brutella westermani* JCM35486, etc.

[0097] Specific examples of Clostridium species include Clostridium butyricum JCMNT, Clostridium medullaris JCM31500T, and Clostridium symbioticum JCM1297T.

[0098] Specific examples of bacteria in the genus Collinsella include Collins aerogenes JCM10188T, Collins enterica JCM10643T, Collins feces JCM10641T, and Collins tanakaei JCM16071T.

[0099] Specific examples of bacteria in the genus Faecalibacterium include Faecalibacterium tsukuri JCM39210, Faecalibacterium longum JCM39208, Faecalibacterium pretonii JCM31915, Faecalibacterium pretonii JCM39207, and Faecalibacterium pretonii JCM39209.

[0100] Specific examples of bacteria in the genus *Faecalicatena* include *Orotica faecalis* JCM1429T, etc.

[0101] Specific examples of the genus *Lacrimispora* include *Lacrimispora vesiculata* JCM15734T, *Lacrimispora pseudowedge-shaped* JCM1415T, and *Lacrimispora xylana* JCM15735T.

[0102] Specific examples of bacteria in the genus Paeniclostridium include, for example, Clostridium soxolense JCM3814T.

[0103] Specific examples of the Parabacteroides genus include Parabacteroides faecalis JCM9497T, etc.

[0104] Specific examples of the genus Roseburia include human Roseburia JCM17582, entero Roseburia JCM17583, and inulin Roseburia JCM17584.

[0105] One preferred method is to use bacteria selected from Lactobacillus rhamnosus CRL1505 or its mutant strain, Gluconacetobacter hansenii or its mutant strain, Lactobacillus acidophilus (GK-1, Lactobacillus acidophilus) L-92 or its mutant strain, Lactobacillus plantarum L-137 or its mutant strain, Lactobacillus bulgaricus OLL1073R-1 or its mutant strain, Lactococcus lactis subsp. lactis JCM5805 or its mutant strain, Lactococcus curvatus JCM1096 or its mutant strain, Lactococcus lactis subsp. lactis ATCC7962 or its mutant strain, and Lactobacillus plantoids. In a more preferred manner, the bacteria may be at least one selected from the group consisting of Lactococcus lactis subsp. lactis JCM5805 or its mutant, Lactococcus curvatus JCM1096 or its mutant, Lactococcus lactis subsp. lactis ATCC7962 or its mutant, and Lactobacillus paraplantarum JCM1149 or its mutant.

[0106] Of the aforementioned lactic acid bacteria and acetic acid bacteria, the JCM strain can be obtained from the Microbial Materials Development Laboratory, Bioresource Center, RIKEN (3-1-1 Takanodai, Tsukuba City, Ibaraki Prefecture, Japan); the NBRC strain can be obtained from the Biogenetic Resources Division, Technical Base for Product Evaluation (2-5-8 Kazusa-Kamazu, Kisarazu City, Chiba Prefecture, Japan); the NRIC strain can be obtained from the Strains Preservation Laboratory, Tokyo University of Agriculture (1-1-1 Sakuragaoka, Setagaya-ku, Tokyo, Japan); and the ATCC strain can be obtained from the American Center for Type Culture Collection (10801 University Avenue, Manassas, Virginia, USA). In addition to being obtained from public institutions, the aforementioned lactic acid bacteria and acetic acid bacteria can also be obtained by isolating or purifying them from commercially available products containing lactic acid bacteria or acetic acid bacteria using known methods.

[0107] As described above, the JCM strains can be obtained from the Microbial Materials Development Laboratory of the RIKEN Center for Biological Resources. This invention can utilize identical strains of the aforementioned JCM strains preserved in institutions other than the RIKEN Center for Biological Resources. Specifically, identical strains of *Lactococcus lactis* subsp. *lactococcus* JCM 5805 can be obtained from the Biogenetic Resources Division of the Technical Base for Product Evaluation (2-5-8 Kazusa-kama-ashi, Kisarazu City, Chiba Prefecture, Japan), the Strains Preservation Laboratory of Tokyo University of Agriculture (1-1-1 Sakuragaoka, Setagaya-ku, Tokyo, Japan), and the American Center for Type Culture Collection (10801 University Avenue, Manassas, Virginia, USA). *Lactococcus lactis* subsp. *lactococcus* JCM 5805 is deposited at the American Center for Type Culture Collection as *Lactococcus lactis* subsp. *lactococcus* ATCC 9936 and *Lactococcus lactis* subsp. *lactococcus* ATCC 19435.

[0108] The mutant strain described above only needs to possess characteristics that enable the achievement of the objectives of this technology (e.g., immune activation ability). Furthermore, the mutant strain is preferably a bacterium with the same bacteriological properties as the described strain and possessing an immune activation ability equal to or greater than that of the described strain. Whether a particular mutant strain possesses an immune activation ability equal to or greater than that of the described strain can be confirmed, for example, by the evaluation method described later or the method described in the embodiments later.

[0109] Such mutant strains can be constructed by non-artificially introducing mutations into the aforementioned strains. Alternatively, such mutant strains can be constructed by artificially introducing mutations into the aforementioned strains. For example, mutations can be introduced into the bacteria by treating them with mutagens such as ultraviolet light (UV) or DNA alkylating agents, or by introducing mutations into the strains through known gene recombination or gene editing methods such as CRISPR-Cas9.

[0110] The bacteria in this embodiment can be cultured using conventional methods depending on the species. For example, when the bacteria are lactic acid bacteria or acetic acid bacteria, they can be cultured using known methods with known culture media. The culture medium is not particularly limited as long as it can promote the proliferation of the bacteria; for example, MRS medium, GAM medium, or a medium with appropriate sugar supplementation in M17 medium can be used, and inorganic salts, vitamins, and / or amino acids can be added as appropriate. Cultivation can be carried out at 25–40°C for several hours to several days.

[0111] The effective amount of bacteria contained in the composition of this embodiment is not particularly limited as long as it is sufficient to exert immune activation capabilities, and can vary depending on the target application. For example, when the target application is mammals such as humans, the lower limit can be set to 1 × 10⁻⁶. 8 1×10 9 One or 1×10 10 The maximum value can be set to, for example, 1 × 10. 14 1×10 13 1×10 12 These upper and lower limits can be combined arbitrarily, and the range of the above intake can be set, for example, as 1 × 10⁻⁶. 8 Above and 1×10 14 Less than one, 1×10 8 Above and 1×10 13 Less than one, 1×10 8 Above and 1×10 12 Less than one, 1×10 9 Above and 1×10 14 Less than one, 1×10 9 Above and 1×10 13 Less than one, 1×10 10 Above and 1×10 14 Less than one, 1×10 10 Above and 1×10 13 Less than one or 1×10 10 Above and 1×10 12 The bacterial count can be determined using known microscopes, flow cytometers, or rapid non-culture microbial testing devices (such as ELESTA PixeeMo (AFI Technologie Co., Ltd.)). From the viewpoint of high versatility, microscope measurement is preferred. As a composition with immune-activating capabilities, it can be used, for example, in the form of food compositions, pharmaceutical compositions, quasi-pharmaceuticals, bacterial raw material powders (powders formed by drying bacterial cells or powders containing them), or animal feed.

[0112] The amount of bacteria with immune-activating ability in the immune-activating composition of one embodiment is not particularly limited, as long as it is an amount sufficient to satisfy the effective amount of immune activation, and therefore can vary depending on the form of the immune-activating composition of this embodiment. For example, relative to the total mass of the immune activation composition of this embodiment, the dried mass of the bacteria in this embodiment can be 0.0001% by mass or more, 0.001% by mass or more, 0.005% by mass or more, 0.01% by mass or more, 0.02% by mass or more, 0.05% by mass or more, 0.10% by mass or more, 0.30% by mass or more, 1.0% by mass or more, 1.5% by mass or more, 2.0% by mass or more, 2.5% by mass or more, 3.0% by mass or more, 5.0% by mass or more, 7.0% by mass or more, or 10.0% by mass or more. It can also be less than 100% by mass, less than 95% by mass, less than 90% by mass, less than 80% by mass, less than 70% by mass, less than 60% by mass, less than 50% by mass, less than 30% by mass, less than 25% by mass, less than 20% by mass, or less than 15% by mass.

[0113] These lower and upper limits can be arbitrarily combined. For example, relative to the total mass of the immune activation composition of this embodiment, the dried mass of the bacteria in this embodiment can be 0.0001% by mass or more and less than 100% by mass, 0.0001% by mass or more and less than 95% by mass, 0.0001% by mass or more and less than 90% by mass, 0.0001% by mass or more and less than 80% by mass, 0.0001% by mass or more and less than 70% by mass, 0.0001% by mass or more and less than 60% by mass, 0.0001% by mass or more and less than 50% by mass, 0.0001% by mass or more and less than 30% by mass, 0.0001% by mass or more and less than 25% by mass, 0.0001% by mass or more, and so on. Quantity ≥ 20% by mass, ≥ 15% by mass, ≥ 100% by mass, ≥ 95% by mass, ≥ 90% by mass, ≥ 80% by mass, ≥ 70% by mass, ≥ 60% by mass, ≥ 50% by mass, ≥ 30% by mass, ≥ 25% by mass, ≥ 20% by mass, ≥ 15% by mass, ≥ 0.005% by mass. The following percentages are considered as high as 100% by mass, 0.005% by mass and 95% by mass, 0.005% by mass and 90% by mass, 0.005% by mass and 80% by mass, 0.005% by mass and 70% by mass, 0.005% by mass and 60% by mass, 0.005% by mass and 50% by mass, 0.005% by mass and 30% by mass, 0.005% by mass and 25% by mass, 0.005% by mass and 20% by mass, 0.005% by mass and 15% by mass, 0.01% by mass and 100% by mass, 0.01% by mass and 95% by mass, and 0.01% by mass. % or more and less than 90% by mass, 0.01% or more and less than 80% by mass, 0.01% or more and less than 70% by mass, 0.01% or more and less than 60% by mass, 0.01% or more and less than 50% by mass, 0.01% or more and less than 30% by mass, 0.01% or more and less than 25% by mass, 0.01% or more and less than 20% by mass, 0.01% or more and less than 15% by mass, 0.02% or more and less than 100% by mass, 0.02% or more and less than 95% by mass, 0.02% or more and less than 90% by mass, 0.02% or more and less than 80% by mass, 0.02% or more and less than 70% by mass, 0.0.02% or more and less than 60% by mass, 0.02% or more and less than 50% by mass, 0.02% or more and less than 30% by mass, 0.02% or more and less than 25% by mass, 0.02% or more and less than 20% by mass, 0.02% or more and less than 15% by mass, 0.05% or more and less than 100% by mass, 0.05% or more and less than 95% by mass, 0.05% or more and less than 90% by mass, 0.05% or more and less than 80% by mass, 0.05% or more and less than 70% by mass, 0.05% or more and less than 60% by mass, 0.05% or more and less than 50% by mass, 0.05% or more and less than 30% by mass Below, 0.05% by mass and below 25% by mass, 0.05% by mass and below 20% by mass, 0.05% by mass and below 15% by mass, 0.10% by mass and below 100% by mass, 0.10% by mass and below 95% by mass, 0.10% by mass and below 90% by mass, 0.10% by mass and below 80% by mass, 0.10% by mass and below 70% by mass, 0.10% by mass and below 60% by mass, 0.10% by mass and below 50% by mass, 0.10% by mass and below 30% by mass, 0.10% by mass and below 25% by mass, 0.10% by mass and below 20% by mass, 0.10% by mass and above 15% by mass Below 1.0% by mass, 0.30% by mass and less than 100% by mass, 0.30% by mass and less than 95% by mass, 0.30% by mass and less than 90% by mass, 0.30% by mass and less than 80% by mass, 0.30% by mass and less than 70% by mass, 0.30% by mass and less than 60% by mass, 0.30% by mass and less than 50% by mass, 0.30% by mass and less than 30% by mass, 0.30% by mass and less than 25% by mass, 0.30% by mass and less than 20% by mass, 0.30% by mass and less than 15% by mass, 1.0% by mass and less than 100% by mass, 1.0% by mass and less than 95% by mass, 1.0% by mass and... Below 90% by mass, above 1.0% by mass and below 80% by mass, above 1.0% by mass and below 70% by mass, above 1.0% by mass and below 60% by mass, above 1.0% by mass and below 50% by mass, above 1.0% by mass and below 30% by mass, above 1.0% by mass and below 25% by mass, above 1.0% by mass and below 20% by mass, above 1.0% by mass and below 15% by mass, above 1.5% by mass and below 100% by mass, above 1.5% by mass and below 95% by mass, above 1.5% by mass and below 90% by mass, above 1.5% by mass and below 80% by mass, above 1.5% by mass and below 70% by mass, above 1.5% by mass and below 60% by mass, 1.5% or more and less than 50% by mass, 1.5% or more and less than 30% by mass, 1.5% or more and less than 25% by mass, 1.5% or more and less than 20% by mass, 1.5% or more and less than 15% by mass, 2.0% or more and less than 100% by mass, 2.0% or more and less than 95% by mass, 2.0% or more and less than 90% by mass, 2.0% or more and less than 80% by mass, 2.0% or more and less than 70% by mass, 2.0% or more and less than 60% by mass, 2.0% or more and less than 50% by mass, 2.0% or more and less than 30% by mass, 2.0% or more and less than 25 ... Less than 0% by mass, more than 2.0% by mass and less than 15% by mass, more than 2.5% by mass and less than 100% by mass, more than 2.5% by mass and less than 95% by mass, more than 2.5% by mass and less than 90% by mass, more than 2.5% by mass and less than 80% by mass, more than 2.5% by mass and less than 70% by mass, more than 2.5% by mass and less than 60% by mass, more than 2.5% by mass and less than 50% by mass, more than 2.5% by mass and less than 30% by mass, more than 2.5% by mass and less than 25% by mass, more than 2.5% by mass and less than 20% by mass, more than 2.5% by mass and less than 15% by mass, more than 3.0% by mass and less than 100% by mass, more than 3.0% by mass and less than 95% by mass, 3 0% or more and less than 90% of mass, 3.0% or more and less than 80% of mass, 3.0% or more and less than 70% of mass, 3.0% or more and less than 60% of mass, 3.0% or more and less than 50% of mass, 3.0% or more and less than 30% of mass, 3.0% or more and less than 25% of mass, 3.0% or more and less than 20% of mass, 3.0% or more and less than 15% of mass, 5.0% or more and less than 100% of mass, 5.0% or more and less than 95% of mass, 5.0% or more and less than 90% of mass, 5.0% or more and less than 80% of mass, 5.0% or more and less than 70% of mass, 5 .... Less than 0% of mass, 5.0% or more and less than 50% of mass, 5.0% or more and less than 30% of mass, 5.0% or more and less than 25% of mass, 5.0% or more and less than 20% of mass, 5.0% or more and less than 15% of mass, 7.0% or more and less than 100% of mass, 7.0% or more and less than 95% of mass, 7.0% or more and less than 90% of mass, 7.0% or more and less than 80% of mass, 7.0% or more and less than 70% of mass, 7.0% or more and less than 60% of mass, 7.0% or more and less than 50% of mass, 7.0% or more and less than 30% of mass, 7.0% or more and less than 25% of mass, 7.The following concentrations of bacteria are permitted for use: 0% to 20% by mass, 7.0% to 15% by mass, 10.0% to less than 100% by mass, 10.0% to 95% by mass, 10.0% to 90% by mass, 10.0% to 80% by mass, 10.0% to 70% by mass, 10.0% to 60% by mass, 10.0% to 50% by mass, 10.0% to 30% by mass, 10.0% to 25% by mass, 10.0% to 20% by mass, and 10.0% to 15% by mass. The above-described dried mass of the bacteria in this embodiment can be used as a daily dosage for an adult weighing 60 kg. This dosage can be set based on factors such as the health status of the person receiving the medication or ingesting it, the method of administration or ingestion, and the combination with other agents.

[0114] The number of immune-activating bacteria in the immune-activating composition of this embodiment can be 1.0 × 10⁻⁶. 3 1.0 × 10⁶ cells / mL or more 4 1.0 × 10⁶ cells / mL or more 5 1.0 × 10⁶ cells / mL or more 6 1.0 × 10⁶ cells / mL or more 7 10 cells / mL or more or 4.0 × 10 7 A cell / mL or higher is acceptable, up to 1.0 × 10⁻⁶ cells / mL. 11 Less than 10 cells / mL, 1.0 × 10 10 Less than 10 cells / mL, 3.0 × 10 9 Less than 1.0 × 10⁻⁶ cells / mL or 1.0 × 10⁻⁶ cells / mL 9 Below 10 cells / mL. These lower and upper limits can be combined arbitrarily; for example, the number of immune-activating bacteria in the immune-activating composition of this embodiment can be 1.0 × 10⁻⁶. 3 More than 1.0 × 10⁻⁶ cells / mL 11 Less than 10 cells / mL, 1.0 × 10 3 More than 1.0 × 10⁻⁶ cells / mL 10 Less than 10 cells / mL, 1.0 × 10 3 More than 3.0 × 10⁶ cells / mL and 3.0 × 10⁶ cells / mL 9 Less than 10 cells / mL, 1.0 × 10 3 More than 1.0 × 10⁻⁶ cells / mL 9 Less than 10 cells / mL, 1.0 × 10 4 More than 1.0 × 10⁻⁶ cells / mL 11 Less than 10 cells / mL, 1.0 × 104 More than 1.0 × 10⁻⁶ cells / mL 10 Less than 10 cells / mL, 1.0 × 10 4 More than 3.0 × 10⁶ cells / mL and 3.0 × 10⁶ cells / mL 9 Less than 10 cells / mL, 1.0 × 10 4 More than 1.0 × 10⁻⁶ cells / mL 9 Less than 10 cells / mL, 1.0 × 10 5 More than 1.0 × 10⁻⁶ cells / mL 11 Less than 10 cells / mL, 1.0 × 10 5 More than 1.0 × 10⁻⁶ cells / mL 10 Less than 10 cells / mL, 1.0 × 10 5 More than 3.0 × 10⁶ cells / mL and 3.0 × 10⁶ cells / mL 9 Less than 10 cells / mL, 1.0 × 10 5 More than 1.0 × 10⁻⁶ cells / mL 9 Less than 10 cells / mL, 1.0 × 10 6 More than 1.0 × 10⁻⁶ cells / mL 11 Less than 10 cells / mL, 1.0 × 10 6 More than 1.0 × 10⁻⁶ cells / mL 10 Less than 10 cells / mL, 1.0 × 10 6 More than 3.0 × 10⁶ cells / mL and 3.0 × 10⁶ cells / mL 9 Less than 10 cells / mL, 1.0 × 10 7 More than 1.0 × 10⁻⁶ cells / mL 11 Less than 10 cells / mL, 1.0 × 10 7 More than 1.0 × 10⁻⁶ cells / mL 10 Less than 10 cells / mL, 1.0 × 10 7 More than 1.0 × 10⁻⁶ cells / mL 9 Less than 10 cells / mL, 4.0 × 10 7 More than 1.0 × 10⁻⁶ cells / mL 11 Less than 10 cells / mL, 4.0 × 10 7 More than 1.0 × 10⁻⁶ cells / mL 10 Less than 10 cells / mL, 4.0 × 10 7 More than 1.0 × 10⁻⁶ cells / mL 9 Cells / mL or less. In this case, the daily intake of the liquid immune activation composition can be more than 10 mL and less than 1000 mL, more than 30 mL and less than 800 mL, more than 50 mL and less than 500 mL, or more than 100 mL and less than 250 mL.

[0115] In the immune activation composition of this embodiment, the number of bacteria with immune activation ability in each unit package of the immune activation composition of one embodiment can be 1.0 × 10⁻⁶. 7 More than 1.0 × 10 8 More than 3.0 × 10 8 More than 5.0 × 10 8 More than one or 1.0 × 10 9 More than 5.0 × 10 9 More than 1.0 × 10 10 More than 5.0 × 10 10 More than one, 1.0 × 10 11 More than one, can be 1.0 × 10 14 Less than 1.0 × 10 13 Less than 1.0 × 10 12 The number of bacteria per unit package of this embodiment may be less than 1.0 × 10⁻⁶. Furthermore, these upper and lower limits can be combined arbitrarily. For example, in the immune activation composition of this embodiment, the number of bacteria per unit package of this embodiment may be 1.0 × 10⁻⁶. 7 More than 1.0 × 10 14 Less than 1.0 × 10 7 More than 1.0 × 10 13 Less than 1.0 × 10 7 More than 1.0 × 10 12 Less than 1.0 × 10 8 More than 1.0 × 10 14 Less than 1.0 × 10 8 More than 1.0 × 10 13 Less than 1.0 × 10 8 More than 1.0 × 10 12 Less than 3.0 × 10 8 More than 1.0 × 10 14 Less than 3.0 × 10 8 More than 1.0 × 10 13 Less than 3.0 × 10 8 More than 1.0 × 10 12 Less than 5.0 × 10 8 More than 1.0 × 10 14 Less than 5.0 × 10 8 More than 1.0 × 10 13 Less than 5.0 × 10 8 More than 1.0 × 10 12 Less than 1.0 × 10 9 More than 1.0 × 10 14Less than 1.0 × 10 9 More than 1.0 × 10 13 Less than 1.0 × 10 9 More than 1.0 × 10 12 Less than 5.0 × 10 9 More than 1.0 × 10 14 Less than 5.0 × 10 9 More than 1.0 × 10 13 Less than 5.0 × 10 9 More than 1.0 × 10 12 Less than 1.0 × 10 10 More than 1.0 × 10 14 Less than 1.0 × 10 10 More than 1.0 × 10 13 Less than 1.0 × 10 10 More than 1.0 × 10 12 Less than 5.0 × 10 10 More than 1.0 × 10 14 Less than 5.0 × 10 10 More than 5.0 × 10 13 Less than 5.0 × 10 10 More than 1.0 × 10 12 Less than 1.0 × 10 11 More than 1.0 × 10 14 Less than 1.0 × 10 11 More than 1.0 × 10 13 Less than 1.0 × 10 11 More than 1.0 × 10 12 The number is below 1.

[0116] "Amino acid" refers to a compound having both an amino group and a carboxyl group. Proline and its derivatives, however, do not have an amino group but rather an imino group, and are still included in the category of amino acids. In this specification, "peptide" refers to a compound consisting of 2 to 50 amino acids linked by peptide bonds. In this specification, "protein" refers to a compound consisting of 51 or more amino acids linked by peptide bonds. "A compound selected from the group consisting of amino acids, peptides, and proteins that enhance the immune-activating ability of bacteria with immune-activating capabilities" refers to the aforementioned compound that enhances the immune-activating effect brought about by bacteria with immune-activating capabilities. This can be a compound whose degree of immune-activating effect is increased when co-cultured with the compound, bacteria with immune-activating capabilities, and immune cells compared to co-culturing only bacteria with immune-activating capabilities and immune cells.

[0117] Regarding whether the compound of this embodiment has an immune-activating effect on bacteria, there is no particular limitation. If the function of immune cells in the presence of immune-activating bacteria is enhanced compared to the absence of the compound, then it is determined that the compound has an immune-activating effect on bacteria. As a more detailed example, whether the compound of this embodiment has an immune-activating effect on bacteria can be confirmed by measuring the increase in IFN-α concentration in the presence of the compound compared to the absence of the compound, according to steps (i') to (iv') below.

[0118] (i') Mouse-derived bone marrow cells, after red blood cells were removed, were processed at a rate of 1 × 10⁻⁶. 6 Cell suspensions were prepared by suspending cells / mL in RPMI medium prepared in such a manner that each component described in the following (Composition of the medium) reaches its respective final concentration described in the following (Composition of the medium), thereby preparing a cell suspension.

[0119] <Composition of the culture medium>

[0120] ·10% by volume FBS

[0121] 100 U / mL penicillin / streptomycin

[0122] 1mM Sodium Pyruvate

[0123] ·2.5mM HEPES

[0124] • 1% by mass of non-essential amino acids (NEAA) for MEM

[0125] 50 μM β-mercaptoethanol

[0126] 100ng / mL Flt-3L

[0127] (ii') Inoculate 1 mL of each of the prepared cell suspensions and incubate them in a CO2 incubator at 37°C and 5% CO2 for 1 week to induce pDC.

[0128] (iii') The induced bone marrow cells containing pDCs were injected at a rate of 2 × 10⁻⁶. 5 The bacterial suspension was suspended at a concentration of 1 mg / mL, and 200 μL was inoculated into each well of a 96-well plate. 2 μL of bacterial suspension was added to each well, and then compound solution was added to the specified concentration.

[0129] (iv) After 24 hours, the culture supernatant was recovered, and the IFN-α concentration was determined by ELISA using an IFN-α assay kit.

[0130] Amino acids exist in both their free and salt forms. They can be either L-amino acids or D-amino acids. Amino acids can be any of the following: acidic amino acids (e.g., aspartic acid and glutamic acid), neutral amino acids (e.g., alanine, asparagine, cysteine, glutamine, glycine, isoleucine, leucine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, cysteine, ornithine, γ-aminobutyric acid, hydroxyproline, selenomethionine, homoserine, β-alanine, δ-aminolevulinic acid, and theanine), and basic amino acids (e.g., arginine, histidine, and lysine). The portion of an amino acid other than the amino and carboxyl groups (especially the side chain in the case of α-amino acids) can be hydrophilic or hydrophobic, may or may not have aromatic groups, may or may not have sulfur, and may or may not have amide groups. Amino acids can be those related to ketone body metabolism (e.g., isoleucine and leucine), amino acids with antioxidant effects (e.g., cysteine, glycine, serine, glutamic acid, and γ-aminobutyric acid), amino acids with immune-activating effects (e.g., cysteine, glycine, glutamic acid, arginine, cystine, and theanine), amino acids with muscle synthesis effects (e.g., isoleucine, leucine, methionine, valine, and lysine), neurotransmitters or amino acids with neurotransmitter synthesis effects (e.g., glutamine, glycine, serine, tryptophan, glutamic acid, and γ-aminobutyric acid), amino acids with collagen synthesis effects (e.g., glycine, proline, and hydroxyproline), and amino acids with anti-anxiety effects (e.g., glycine, serine, tryptophan, glutamic acid, and γ-aminobutyric acid). Specific amino acids that can be listed include alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, cystine, ornithine, γ-aminobutyric acid, hydroxyproline, selenomethionine, homoserine, β-alanine, δ-aminolevulinic acid, and theanine.

[0131] As amino acids that enhance the immune activation of bacteria with immune-activating capabilities, acidic amino acids (such as aspartic acid and glutamic acid), neutral amino acids (such as alanine, asparagine, cysteine, glutamine, isoleucine, leucine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, cystine, ornithine, γ-aminobutyric acid, hydroxyproline, homoserine, β-alanine, δ-aminolevulinic acid and theanine) or basic amino acids (such as arginine, histidine and lysine) are preferred. Amino acids that enhance the immune activation of bacteria with immune-activating capabilities are preferably those related to ketone body metabolism (e.g., isoleucine and leucine), those with antioxidant effects (e.g., cysteine, serine, glutamic acid, and γ-aminobutyric acid), those with immune-activating effects (e.g., cysteine, glutamic acid, arginine, cystine, and theanine), those with muscle synthesis effects (e.g., isoleucine, leucine, valine, and lysine), those that are neurotransmitters or have neurotransmitter synthesis effects (e.g., glutamine, serine, tryptophan, glutamic acid, and γ-aminobutyric acid), those that have collagen synthesis effects (e.g., proline and hydroxyproline), and those with anti-anxiety effects (e.g., serine, tryptophan, glutamic acid, and γ-aminobutyric acid). The amino acid that enhances the immune activation ability of bacteria with immune-activating capabilities is preferably a compound selected from the group consisting of alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, histidine, isoleucine, leucine, lysine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, cystine, ornithine, γ-aminobutyric acid, hydroxyproline, homoserine, β-alanine, δ-aminolevulinic acid, and theanine. More preferably, it includes compounds selected from alanine and asparagine. The amino acids are amide, cysteine, glutamine, leucine, proline, threonine, tryptophan, valine, arginine, histidine, lysine, isoleucine, serine, ornithine, and cystine, with more preferred amino acids being one or more compounds from the group consisting of L-alanine, L-asparagine, L-cysteine, L-glutamine, L-leucine, L-proline, L-threonine, L-tryptophan, L-valine, L-arginine, L-histidine, L-lysine, L-isoleucine, L-serine, L-ornithine, and L-cystine.

[0132] Peptides and proteins include any form, both free and salt-based. The amino acids constituting peptides and proteins can be either L-amino acids or D-amino acids. The number of amino acids constituting a peptide can be 2–20 (oligopeptide) or 21–50. The number of amino acids in an oligopeptide can be any of 2 (dipeptide), 3 (tripeptide), 4 (tetrapeptide), 5 (pentapeptide), 6 (hexapeptide), 7 (heptapeptide), 8 (octapeptide), 9 (nonapeptide), 10 (decapeptide), 11, 12, 13, 14, 15, 16, 17, 18, 19, and 20. Peptides and proteins can be derived from plants (e.g., rice, wheat, barley, corn, soybeans, and peas) or animals (e.g., cattle, pigs, chickens, sheep, sardines, herring, mackerel, skipjack tuna, and tuna). Additionally, peptides can be breakdown products of proteins (e.g., breakdown products obtained using hydrolytic enzymes). Peptides can be categorized as follows: peptides with antioxidant properties (e.g., glutathione and imidazole peptides); peptides with gelling properties (e.g., casein and whey protein breakdown products); peptides that promote lactic acid breakdown (e.g., imidazole peptides); peptides that regulate uric acid levels (e.g., imidazole peptides); peptides that buffer muscle pH reduction (e.g., imidazole peptides); and peptides that stimulate calcium transport and calcium metabolism. 2+ - Peptides that act on ATPases (e.g., imidazole peptides). Specific proteins (e.g., proteins that are the source of peptides but are not yet broken down) include elastin, collagen, silk proteins (e.g., fibroin and sericin), wheat gluten, and milk proteins (casein and whey protein). Furthermore, glutathione and imidazole dipeptides are examples of peptides. Glutathione is a tripeptide composed of glutamic acid, cysteine, and glycine, preferably reduced glutathione (GSH). Imidazole dipeptides are a general term for dipeptides containing histidine or methylhistidine, specifically including carnosine (β-alanyl-histidine), anserine (β-alanyl-1-methylhistidine), cetylcarnosine (β-alanyl-3-methylhistidine), and homocarnosine (γ-aminobutyric acid-histidine). Preferred peptides include GSH, imidazole dipeptide, silk peptides, sardine-derived peptides, casein breakdown products, collagen peptides, wheat protein breakdown products, and whey protein breakdown products. Preferred proteins include elastin and milk proteins.

[0133] Peptides or proteins that enhance the immune-activating ability of bacteria with immune-activating capabilities are preferably derived from plants (e.g., rice, wheat, barley, corn, soybeans, and peas) or animals (e.g., cattle, pigs, chickens, sheep, sardines, herring, mackerel, skipjack tuna, and tuna). Furthermore, peptides that enhance the immune-activating ability of bacteria with immune-activating capabilities are preferably protein breakdown products (e.g., breakdown products obtained using hydrolytic enzymes). Peptides that enhance the immune-activating ability of bacteria with immune-activating capabilities can be peptides with antioxidant effects (e.g., glutathione and imidazole peptides), peptides with gelling effects (e.g., casein breakdown products and whey protein breakdown products), peptides that promote lactate breakdown (e.g., imidazole peptides), peptides that regulate uric acid levels (e.g., imidazole peptides), peptides that buffer muscle pH reduction (e.g., imidazole peptides), and peptides that stimulate calcium transport and Ca2+ metabolism. 2+ - Peptides that act as ATPases (e.g., imidazole peptides). Proteins that enhance the immune-activating capacity of bacteria with immune-activating abilities (e.g., proteins that are the source of peptides but are not yet broken down) are preferably elastin, collagen, silk proteins (e.g., fibroin, sericin, etc.), wheat gluten, casein, and whey protein. Furthermore, glutathione and imidazole dipeptides are preferably examples of peptides that enhance the immune-activating capacity of bacteria with immune-activating abilities. Imidazole dipeptides preferably include carnosine (β-alanyl-histidine), anserin (β-alanyl-1-methylhistidine), cetirin (β-alanyl-3-methylhistidine), and homocarnosine (γ-aminobutyric acid-histidine). GSH, imidazole dipeptides, silk peptides, sardine-derived peptides, casein breakdown products, collagen peptides, wheat protein breakdown products, and whey protein breakdown products are also preferred examples of peptides that enhance the immune-activating capacity of bacteria with immune-activating abilities. Proteins that enhance the immune activation of bacteria with immune-activating capabilities are preferably examples such as elastin.

[0134] The compound selected is one or more compounds from the group consisting of amino acids, peptides, and proteins that enhance the immune activation ability of bacteria with immune-activating capabilities. Preferably, it is a compound selected from the group consisting of alanine, asparagine, cysteine, glutamine, leucine, proline, threonine, tryptophan, valine, arginine, histidine, lysine, ornithine, cystine, glutathione, imidazole dipeptide, silk peptide, sardine-derived peptide, casein breakdown product, collagen peptide, wheat protein breakdown product, whey protein breakdown product, and elastin.

[0135] Silk peptides can be obtained by hydrolyzing the fibrous proteins (silk fibroin) of silk using enzymes. For example, "Brain Memory Essence" manufactured by Chuo Pharmaceutical in Japan can be used.

[0136] Sardin-derived peptides can be peptides obtained by enzymatic hydrolysis of sardine proteins using alkaline protease, such as the "Pepitate α-1000N" manufactured by Senmi Ecosu.

[0137] Casein breakdown products are sometimes called casein peptides. Casein breakdown products obtained by enzymatic hydrolysis can be used, for example, Nippon Shin-Yakusei's "CE90GMM".

[0138] Collagen peptides can be, for example, chicken collagen peptides. Chicken collagen peptides can be obtained by extracting and purifying collagen peptides from chicken feet (from Japan or other countries). For example, "C-LAP" made from Japanese ham can be used.

[0139] Imidazole dipeptide can be obtained by extracting and purifying chicken breast meat (from Japan or abroad), for example, the Japanese preventive medicine brand "Imida peptide".

[0140] Enzymatic decomposition of wheat protein can utilize substances obtained by hydrolyzing gluten with enzymes, such as "Meripro 500" manufactured by Koyo Shokai.

[0141] Whey protein breakdown products can be substances obtained by hydrolyzing whey protein using enzymes, such as "LE80GF-US" from Nippon Shin-Yaku Corporation or "Whey Peptide HW-3" from Snow Brand Milk Products Co., Ltd.

[0142] Elastin can be a substance obtained by enzymatic hydrolysis after pretreatment of animal biological tissues (which may be further separated and purified depending on the circumstances). For example, "Puella elastin" manufactured by the Biotalis Applied Research Institute can be used.

[0143] Milk protein can be produced using milk protein itself or whey protein concentrate made from milk protein through ultrafiltration, for example, using Nippon Shin-Yakusei's "PROGEL800".

[0144] Regarding the bacterial immune-activating effect of the compound of this embodiment, compared with the absence of the compound, the IFN-α concentration measured according to steps (i') to (iv') above, in the presence of the compound, is preferably 1.01 times or more, 1.02 times or more, 1.03 times or more, 1.05 times or more, 1.08 times or more, 1.10 times or more, 1.13 times or more, 1.15 times or more, 1.18 times or more, 1.20 times or more, and 1.23 times or more. The upper and lower limits are: above 1.25 times, above 1.28 times, above 1.30 times, above 1.40 times, above 1.50 times, above 1.60 times, above 1.70 times, above 1.80 times, above 1.90 times, or above 2.0 times. Preferably, the upper and lower limits are below 4.0 times, below 3.8 times, below 3.5 times, below 3.3 times, below 3.0 times, below 2.8 times, below 2.5 times, below 2.3 times, below 2.0 times, below 1.80 times, or below 1.50 times. These upper and lower limits can be combined arbitrarily. Regarding the bacterial immune activation enhancement effect of the compound of this embodiment, compared with the absence of the compound, the IFN-α concentration measured according to steps (i') to (iv') above in the presence of the compound is preferably, for example, 1.01 times or more and 4.0 times or less, 1.01 times or more and 4.0 times or less, 1.01 times or more and 3.8 times or less, 1.01 times or more and 3.5 times or less, 1.01 times or more and 3.3 times or less, or 1.01 times or more. And below 3.0 times, above 1.01 times and below 2.8 times, above 1.01 times and below 2.5 times, above 1.01 times and below 2.3 times, above 1.01 times and below 2.0 times, above 1.01 times and below 1.8 times, above 1.01 times and below 1.5 times, above 1.02 times and below 4.0 times, above 1.02 times and below 3.8 times, above 1.02 times and below 3.5 times, above 1.02 times and below 3.3 times, 1.0 More than 2 times but less than 3.0 times, more than 1.02 times but less than 2.8 times, more than 1.02 times but less than 2.5 times, more than 1.02 times but less than 2.3 times, more than 1.02 times but less than 2.0 times, more than 1.02 times but less than 1.8 times, more than 1.02 times but less than 1.5 times, more than 1.03 times but less than 4.0 times, more than 1.03 times but less than 3.8 times, more than 1.03 times but less than 3.5 times, more than 1.03 times but less than 3.3 times Below, 1.03 times and below 3.0 times, 1.03 times and below 2.8 times, 1.03 times and below 2.5 times, 1.03 times and below 2.3 times, 1.03 times and below 2.0 times, 1.03 times and below 1.8 times, 1.02 times and below 1.5 times, 1.05 times and below 4.0 times, 1.05 times and below 3.8 times, 1.05 times and below 3.5 times, 1.05 times and above 3.0 times.Below 3 times, 1.05 times and below 3.0 times, 1.05 times and below 2.8 times, 1.05 times and below 2.5 times, 1.05 times and below 2.3 times, 1.05 times and below 2.0 times, 1.05 times and below 1.8 times, 1.05 times and below 1.5 times, 1.08 times and below 4.0 times, 1.08 times and below 3.8 times, 1.08 times and below 3.5 times, 1.08 times and below 3.3 times, 1.08 times and below 3.0 times, 1.08 times and below 2.8 times, 1.08 times and below 2.5 times, 1.08 times and below 2.3 times, 1.08 times and below 2.0 times, 1.08 times and above. And below 1.8 times, above 1.08 times but below 1.5 times, above 1.10 times but below 4.0 times, above 1.10 times but below 3.8 times, above 1.10 times but below 3.5 times, above 1.10 times but below 3.3 times, above 1.10 times but below 3.0 times, above 1.10 times but below 2.8 times, above 1.10 times but below 2.5 times, above 1.10 times but below 2.3 times, above 1.10 times but below 2.0 times, above 1.10 times but below 1.8 times, above 1.10 times but below 1.5 times, above 1.13 times but below 4.0 times, above 1.13 times but below 3.8 times, above 1.13 times but below 3.5 times, above 1.13 times but below 3.3 times, 1.1 3 times or more but less than 3.0 times, 1.13 times or more but less than 2.8 times, 1.13 times or more but less than 2.5 times, 1.13 times or more but less than 2.3 times, 1.13 times or more but less than 2.0 times, 1.13 times or more but less than 1.8 times, 1.13 times or more but less than 1.5 times, 1.15 times or more but less than 4.0 times, 1.15 times or more but less than 3.8 times, 1.15 times or more but less than 3.5 times, 1.15 times or more but less than 3.3 times, 1.15 times or more but less than 3.0 times, 1.15 times or more but less than 2.8 times, 1.15 times or more but less than 2.5 times, 1.15 times or more but less than 2.3 times, 1.15 times or more but less than 2.0 times, 1.15 times or more but less than 1.8 times. 1.15 times or more but less than 1.5 times, 1.18 times or more but less than 4.0 times, 1.18 times or more but less than 3.8 times, 1.18 times or more but less than 3.5 times, 1.18 times or more but less than 3.3 times, 1.18 times or more but less than 3.0 times, 1.18 times or more but less than 2.8 times, 1.18 times or more but less than 2.5 times, 1.18 times or more but less than 2.3 times, 1.18 times or more but less than 2.0 times, 1.18 times or more but less than 1.8 times, 1.18 times or more but less than 1.5 times, 1.20 times or more but less than 4.0 times, 1.20 times or more but less than 3.8 times, 1.20 times or more but less than 3.5 times, 1.20 times or more but less than 3.3 times, 1.20 times or more but less than 3.0 times.Below 0 times, above 1.20 times and below 2.8 times, above 1.20 times and below 2.5 times, above 1.20 times and below 2.3 times, above 1.20 times and below 2.0 times, above 1.20 times and below 1.8 times, above 1.20 times and below 1.5 times, above 1.23 times and below 4.0 times, above 1.23 times and below 3.8 times, above 1.23 times and below 3.5 times, above 1.23 times and below 3.3 times, above 1.23 times and below 3.0 times, above 1.23 times and below 2.8 times, above 1.23 times and below 2.5 times, above 1.23 times and below 2.3 times, above 1.23 times and below 2.0 times, above 1.23 times and below 1.8 times, 1.23 times and below 1.23 times. The following are listed: 1.25 times and below 1.5 times, 1.25 times and below 4.0 times, 1.25 times and below 3.8 times, 1.25 times and below 3.5 times, 1.25 times and below 3.3 times, 1.25 times and below 3.0 times, 1.25 times and below 2.8 times, 1.25 times and below 2.5 times, 1.25 times and below 2.3 times, 1.25 times and below 2.0 times, 1.25 times and below 1.8 times, 1.25 times and below 1.5 times, 1.28 times and below 4.0 times, 1.28 times and below 3.8 times, 1.28 times and below 3.5 times, 1.28 times and below 3.3 times, 1.28 times and below 3.0 times. Below, 1.28 times and below 2.8 times, 1.28 times and below 2.5 times, 1.28 times and below 2.3 times, 1.28 times and below 2.0 times, 1.28 times and below 1.8 times, 1.28 times and below 1.5 times, 1.30 times and below 4.0 times, 1.30 times and below 3.8 times, 1.30 times and below 3.5 times, 1.30 times and below 3.3 times, 1.30 times and below 3.0 times, 1.30 times and below 2.8 times, 1.30 times and below 2.5 times, 1.30 times and below 2.3 times, 1.30 times and below 2.0 times, 1.30 times and below 1.8 times, 1.30 times and above And below 1.5 times, above 1.40 times and below 4.0 times, above 1.40 times and below 3.8 times, above 1.40 times and below 3.5 times, above 1.40 times and below 3.3 times, above 1.40 times and below 3.0 times, above 1.40 times and below 2.8 times, above 1.40 times and below 2.5 times, above 1.40 times and below 2.3 times, above 1.40 times and below 2.0 times, above 1.40 times and below 1.8 times, above 1.40 times and below 1.5 times, above 1.50 times and below 4.0 times, above 1.50 times and below 3.8 times, above 1.50 times and below 3.5 times, above 1.50 times and below 3.3 times, above 1.50 times and below 3.0 times, 1.50 times or more but less than 2.8 times, 1.50 times or more but less than 2.5 times, 1.50 times or more but less than 2.3 times, 1.50 times or more but less than 2.0 times, 1.50 times or more but less than 1.8 times, 1.60 times or more but less than 4.0 times, 1.60 times or more but less than 3.8 times, 1.60 times or more but less than 3.5 times, 1.60 times or more but less than 3.3 times, 1.60 times or more but less than 3.0 times, 1.60 times or more but less than 2.8 times, 1.60 times or more but less than 2.5 times, 1.60 times or more but less than 2.3 times Below, 1.60 times and below 2.0 times, 1.60 times and above 1.8 times, 1.70 times and above 4.0 times, 1.70 times and above 3.8 times, 1.70 times and above 3.5 times, 1.70 times and above 3.3 times, 1.70 times and above 3.0 times, 1.70 times and above 2.8 times, 1.70 times and above 2.5 times, 1.70 times and above 2.3 times, 1.70 times and above 2.0 times, 1.70 times and above 1.8 times, 1.80 times and above Below 4.0 times, above 1.80 times and below 3.8 times, above 1.80 times and below 3.5 times, above 1.80 times and below 3.3 times, above 1.80 times and below 3.0 times, above 1.80 times and below 2.8 times, above 1.80 times and below 2.5 times, above 1.80 times and below 2.3 times, above 1.80 times and below 2.0 times, above 1.90 times and below 4.0 times, above 1.90 times and below 3.8 times, above 1.90 times and below 3.5 times, above 1.90 times and below 3.3 times, ...80 times and below 3.8 times, above 1.90 times and below 3.5 times, above 1.90 times and below 3.3 times, 1.90 times and below 4.0 times, above 1.80 times and below 3.8 times, above 1.80 times and below 3.5 times, above 1.90 times and below 3.3 times, 1.90 times and below 4.0 times, above 1.90 times and below 3.8 times, The following are considered high-to-low rates: 1.90 times and below 3.0 times; 1.90 times and below 2.8 times; 1.90 times and below 2.5 times; 1.90 times and below 2.3 times; 1.90 times and below 2.0 times; 2.00 times and below 4.0 times; 2.00 times and below 3.8 times; 2.00 times and below 3.5 times; 2.00 times and below 3.3 times; 2.00 times and below 3.0 times; 2.00 times and below 2.8 times; 2.00 times and below 2.5 times; 2.00 times and below 2.3 times.

[0145] In one embodiment of the immune-activating composition, the lower limit of the content of one or more compounds selected from the group consisting of amino acids, peptides, and proteins, relative to the total amount of the immune-activating composition, can be set, for example, to 0.000001% by mass or more, 0.00001% by mass or more, 0.001% by mass or more, 0.01% by mass or more, 0.02% by mass or more, 0.05% by mass or more, 0.1% by mass or more, 0.5% by mass or more, 1% by mass or more, or 2% by mass or more. Furthermore, the upper limit can be... The upper and lower limits are set to below 90.0% mass, 85.0% mass, 80.0% mass, 75.0% mass, 50.0% mass, 25.0% mass, 10.0% mass, 5.0% mass, 1.0% mass, 0.80% mass, 0.50% mass, 0.30% mass, 0.25% mass, 0.20% mass, 0.10% mass, 0.05% mass, 0.02% mass, or 0.01% mass. These upper and lower limits can be combined arbitrarily. In one embodiment of the immune-activating composition, the content of one or more compounds selected from the group consisting of amino acids, peptides, and proteins, relative to the total amount of the immune-activating composition, may be, for example, 0.000001% by mass or more and 90.0% by mass or less, 0.000001% by mass or more and 85.0% by mass or less, 0.000001% by mass or more and 80.0% by mass or less, 0.000001% by mass or more and 75.0% by mass or less, 0.000001% by mass or more and 50.0% by mass or less, 0.000001% by mass or more and 25.0% by mass or less, 0.000001% by mass or more and 10.0% by mass or less, 0.000001% by mass or more and 5.0% by mass or less, 0.000001% by mass or more and 1.0% by mass or less, 0.000001% by mass or more and 0.80% by mass or less. 0.000001% or more and less than 0.50% by mass, 0.000001% or more and less than 0.30% by mass, 0.000001% or more and less than 0.25% by mass, 0.000001% or more and less than 0.20% by mass, 0.000001% or more and less than 0.10% by mass, 0.000001% or more and less than 0.05% by mass, 0.000001% by mass Above and below 0.02% by mass, above 0.000001% by mass and below 0.01% by mass, above 0.00001% by mass and below 90.0% by mass, above 0.00001% by mass and below 85.0% by mass, above 0.00001% by mass and below 80.0% by mass, above 0.00001% by mass and below 75.0% by mass, above 0.00001% by mass and below 50.0% by mass, 0.0.00001% or more and less than 25.0% of mass, 0.00001% or more and less than 10.0% of mass, 0.00001% or more and less than 5.0% of mass, 0.00001% or more and less than 1.0% of mass, 0.00001% or more and less than 0.80% of mass, 0.00001% or more and less than 0.50% of mass, 0.00001% or more and less than 0.30% of mass, 0.00001% or more and less than 0.25% of mass, 0.00001% or more and less than 0.20% of mass, 0.00001% or more and less than 0.10% of mass, 0.00001% or more and less than 0.05% of mass, 0 0.00001% or more and less than 0.02% of mass, 0.00001% or more and less than 0.01% of mass, 0.001% or more and less than 90.0% of mass, 0.001% or more and less than 85.0% of mass, 0.001% or more and less than 80.0% of mass, 0.001% or more and less than 75.0% of mass, 0.001% or more and less than 50.0% of mass, 0.001% or more and less than 25.0% of mass, 0.001% or more and less than 10.0% of mass, 0.001% or more and less than 5.0% of mass, 0.001% or more and less than 1.0% of mass, 0.001% or more and less than 0.80% of mass. Below, 0.001% by mass and below 0.50% by mass, 0.001% by mass and below 0.30% by mass, 0.001% by mass and below 0.25% by mass, 0.001% by mass and below 0.20% by mass, 0.001% by mass and below 0.10% by mass, 0.001% by mass and below 0.05% by mass, 0.001% by mass and below 0.02% by mass, 0.001% by mass and below 0.01% by mass, 0.01% by mass and below 90.0% by mass, 0.01% by mass and below 85.0% by mass, 0.01% by mass and below 80.0% by mass, 0.01% by mass and below 75.0% by mass. 0.01% or more and less than 50.0% of mass, 0.01% or more and less than 25.0% of mass, 0.01% or more and less than 10.0% of mass, 0.01% or more and less than 5.0% of mass, 0.01% or more and less than 1.0% of mass, 0.01% or more and less than 0.80% of mass, 0.01% or more and less than 0.50% of mass, 0.01% or more and less than 0.30% of mass, 0.01% or more and less than 0.25% of mass, 0.01% or more and less than 0.20% of mass, 0.01% or more and less than 0.10% of mass, 0.01% or more and less than 0.05% of mass, 0.01% or more and less than 0.05% of mass.Less than 0.02% by mass, more than 0.02% by mass and less than 90.0% by mass, more than 0.02% by mass and less than 85.0% by mass, more than 0.02% by mass and less than 80.0% by mass, more than 0.02% by mass and less than 75.0% by mass, more than 0.02% by mass and less than 50.0% by mass, more than 0.02% by mass and less than 25.0% by mass, more than 0.02% by mass and less than 10.0% by mass, more than 0.02% by mass and less than 5.0% by mass, more than 0.02% by mass and less than 1.0% by mass, more than 0.02% by mass and less than 0.80% by mass, more than 0.02% by mass and less than 0.50% by mass, more than 0.02% by mass and less than 0.30% by mass, 0. 0.02% or more and less than 0.25%; 0.02% or more and less than 0.20%; 0.02% or more and less than 0.10%; 0.02% or more and less than 0.05%; 0.05% or more and less than 90.0%; 0.05% or more and less than 85.0%; 0.05% or more and less than 80.0%; 0.05% or more and less than 75.0%; 0.05% or more and less than 50.0%; 0.05% or more and less than 25.0%; 0.05% or more and less than 10.0%; 0.05% or more and less than 5.0%; 0.05% or more and less than 1. Less than 0% by mass, more than 0.05% by mass and less than 0.80% by mass, more than 0.05% by mass and less than 0.50% by mass, more than 0.05% by mass and less than 0.30% by mass, more than 0.05% by mass and less than 0.25% by mass, more than 0.05% by mass and less than 0.20% by mass, more than 0.05% by mass and less than 0.10% by mass, more than 0.10% by mass and less than 90.0% by mass, more than 0.10% by mass and less than 85.0% by mass, more than 0.10% by mass and less than 80.0% by mass, more than 0.10% by mass and less than 75.0% by mass, more than 0.10% by mass and less than 50.0% by mass, more than 0.10% by mass and less than 25.0% by mass, 0. 10% or more and less than 10.0% by mass, 0.10% or more and less than 5.0% by mass, 0.10% or more and less than 1.0% by mass, 0.10% or more and less than 0.80% by mass, 0.10% or more and less than 0.50% by mass, 0.10% or more and less than 0.30% by mass, 0.10% or more and less than 0.25% by mass, 0.10% or more and less than 0.20% by mass, 0.50% or more and less than 90.0% by mass, 0.50% or more and less than 85.0% by mass, 0.50% or more and less than 80.0% by mass, 0.50% or more and less than 75.0% by mass, 0.50% or more and less than 50%.Less than 0% by mass, more than 0.50% by mass and less than 25.0% by mass, more than 0.50% by mass and less than 10.0% by mass, more than 0.50% by mass and less than 5.0% by mass, more than 0.50% by mass and less than 1.0% by mass, more than 0.50% by mass and less than 0.80% by mass, more than 1% by mass and less than 90.0% by mass, more than 1% by mass and less than 85.0% by mass, more than 1% by mass and less than 80.0% by mass, more than 1% by mass and less than 75.0% by mass, more than 1% by mass and less than 50.0% by mass. The following are acceptable weight percentages: 1% or more and less than 25.0%; 1% or more and less than 10.0%; 1% or more and less than 5.0%; 2% or more and less than 90.0%; 2% or more and less than 85.0%; 2% or more and less than 80.0%; 2% or more and less than 75.0%; 2% or more and less than 50.0%; 2% or more and less than 25.0%; 2% or more and less than 10.0%; 2% or more and less than 5.0%.

[0146] In one embodiment of the immune-activating composition, the lower limit of the ratio (mass %) of the content of immune-activating bacteria to the content (mass %) of one or more compounds selected from the group consisting of amino acids, peptides, and proteins ((content of immune-activating bacteria) / (content of one or more compounds selected from the group consisting of amino acids, peptides, and proteins)) can be set, for example, to 0.001 or more, 0.003 or more, 0.005 or more, 0.01 or more, 0.015 or more, 0.02 or more, 0.025 or more, or 0.03 or more. The upper limit can be set to 50,000 or less, 10,000 or less, 1,000 or less, 500 or less, 100 or less, 50 or less, 10 or less, 5 or less, 1.0 or less, 0.75 or less, 0.5 or less, or 0.3 or less. These upper and lower limits can be arbitrarily combined. In one embodiment of the immune-activating composition, the ratio (mass %) of the content of bacteria with immune-activating ability to the content (mass %) of one or more compounds selected from the group consisting of amino acids, peptides, and proteins ((content of bacteria with immune-activating ability) / (content of one or more compounds selected from the group consisting of amino acids, peptides, and proteins)) can, for example, be 0.001 or more and 50,000 or less, 0.001 or more and 10,000 or less, or 0.001 or more and 1,000 or less. Below, 0.001 and below 500, 0.001 and below 100, 0.001 and below 50, 0.001 and below 10, 0.001 and below 5, 0.001 and below 1.0, 0.001 and below 0.75, 0.001 and below 0.5, 0.001 and below 0.3, 0.003 and below 50000, 0.003 and below 10000, 0.003 and below 1000, 0. 0.003 and above, ... And below 500, above 0.005 and below 100, above 0.005 and below 50, above 0.005 and below 10, above 0.005 and below 5, above 0.005 and below 1.0, above 0.005 and below 0.75, above 0.005 and below 0.5, above 0.005 and below 0.3, above 0.01 and below 50000, above 0.01 and below 10000, above 0.01 and below 1000, above 0.01 and below 500, 0.01 and below 100, 0.01 and below 50, 0.01 and below 10, 0.01 and below 5, 0.01 and below 1.0, 0.01 and below 0.75, 0.01 and below 0.5, 0.01 and below 0.3, 0.015 and below 50000, 0.015 and below 10000, 0.015 and below 1000, 0.015 and below 500, 0.015 and below 100, 0.015 and below 50, 0 .015 and below 10, 0.015 and below 5, 0.015 and below 1.0, 0.015 and below 0.75, 0.015 and below 0.5, 0.015 and below 0.3, 0.02 and below 50000, 0.02 and below 10000, 0.02 and below 1000, 0.02 and below 500, 0.02 and below 100, 0.02 and below 50, 0.02 and below 10, 0.02 and below 5, 0.0 2 or higher and 1.0 or lower, 0.02 or higher and 0.75 or lower, 0.02 or higher and 0.5 or lower, 0.02 or higher and 0.3 or lower, 0.025 or higher and 50000 or lower, 0.025 or higher and 10000 or lower, 0.025 or higher and 500 or lower, 0.025 or higher and 100 or lower, 0.025 or higher and 50 or lower, 0.025 or higher and 100 or lower, 0.025 or higher and 100 or lower, 0.025 or higher and 50 or lower, 0.025 or higher and 1.0 or lower, 0.025 or higher and 0.75 Below, 0.025 and below 0.5, 0.025 and below 0.3, 0.03 and below 50000, 0.03 and below 10000, 0.03 and below 1000, 0.03 and below 500, 0.03 and below 100, 0.03 and below 50, 0.03 and below 10, 0.03 and below 5, 0.03 and below 1.0, 0.03 and below 0.75, 0.03 and below 0.5, 0.03 and below 0.3.

[0147] One embodiment of the immune-activating composition can be a food (including beverages), a pharmaceutical, or a quasi-pharmaceutical. The food, pharmaceutical, or quasi-pharmaceutical can be manufactured according to conventional methods. The content of immune-activating bacteria and one or more compounds selected from the group consisting of amino acids, peptides, and proteins in the food, pharmaceutical, or quasi-pharmaceutical is not particularly limited and can be freely set according to the purpose.

[0148] When the immune-activating composition of one embodiment is a food, pharmaceutical, or quasi-pharmaceutical, in addition to containing bacteria with immune-activating capabilities and one or more compounds selected from the group consisting of amino acids, peptides, and proteins, it may also contain ingredients commonly used in food, pharmaceutical, or quasi-pharmaceutical products. The food, pharmaceutical, or quasi-pharmaceutical of one embodiment may contain bases, carriers, additives, etc., commonly used in food, pharmaceutical, or quasi-pharmaceutical products. Examples of additives include, for example, excipients, oils, powders, buffers, solubilizers, antioxidants, surfactants, thickeners, preservatives, pH adjusters, chelating agents, stabilizers, irritant reducers, preservatives, pigments, colorants, fragrances, gloss enhancers, gelling agents, alcohols, water-soluble polymers, film-forming agents, resins, etc. One or more of the bases, carriers, and the various additives described above may be used as needed.

[0149] When the immune-activating composition of one embodiment is a food product, the food product may include, for example, health foods, functional foods, nutritional compositions, nutritional supplements, supplements, health foods, foods for specific health purposes, nutritionally functional foods, or functionally labeled foods. Such food compositions may be labeled, for example, to help healthy individuals maintain immune function (immune care), for those concerned about weakened immune function, or to inhibit weakened immune function. Furthermore, the immune-activating composition of one embodiment may also be used as a food additive.

[0150] Examples of food products that can be categorized include seasonings, processed meat products, processed agricultural products, beverages (lactic acid bacteria beverages, soft drinks, alcoholic beverages, carbonated beverages, milk beverages, fruit juice beverages, tea, coffee, nutritional beverages, etc.), powdered beverages (fruit juice powder, soup powder, milk powder, etc.), concentrated beverages, snacks (candy (throat lozenges), cookies, biscuits, chewing gum, soft candy, chewable tablets, tablets, chocolate, etc.), bread, and cereal products. Additionally, in the case of specific health foods, nutritional functional foods, and functionally labeled foods, the product can be in the form of capsules, granules, powders, syrups, or lozenges.

[0151] When the immune-activating composition in one embodiment is a pharmaceutical or quasi-pharmaceutical, the dosage form of the pharmaceutical or quasi-pharmaceutical may be, for example, a liquid, suspension, capsule, granule, pill, powder, tablet, syrup, tablet-containing solution, etc. Indications for the pharmaceutical include allergy, obesity, heart failure, etc.

[0152] One embodiment of the immune-activating composition is preferably administered or ingested. The administration or ingestion can be oral or non-oral, but oral administration or ingestion is preferred. One embodiment of the immune-activating composition can be administered or ingested only once, or multiple times. Where sustained immune activation is desired, continuous or intermittent administration or ingestion over a certain period is preferred. One embodiment of the food composition can, for example, be ingested at frequencies of 1-5 times per day, once every 2 days, once every 3 days, once every 4 days, or once per week for more than one week, more than two weeks, more than one month, more than three months, more than six months, more than one year, more than three years, more than five years, or more than ten years.

[0153] One embodiment of the immune-activating composition is a composition for immune activation induced by bacteria with immune-activating capabilities, comprising one or more compounds selected from the group consisting of amino acids, peptides, and proteins that enhance the immune-activating capabilities of the aforementioned bacteria. "Immune activation induced by bacteria with immune-activating capabilities" refers to immune activation induced by the inherent function of the bacteria with immune-activating capabilities in activating (activating) immune cells.

[0154] One embodiment of the immune-activating composition is an immune-activating composition or an immune-activating composition with enhanced immune activation, formed by adding one or more compounds selected from the group consisting of amino acids, peptides, and proteins that enhance the immune-activating ability of the bacteria to bacteria with immune-activating ability. This immune-activating composition or immune-activating composition with enhanced immune activation is preferred from the viewpoint that the addition of the compound enhances the immune-activating ability of the bacteria.

[0155] [Enhancers of immune activation induced by bacteria with immune-activating capabilities]

[0156] The second embodiment of this disclosure relates to an enhancer (hereinafter also simply referred to as "enhancer") for immune activation induced by bacteria with immune-activating capabilities. One type of enhancer contains bacteria with immune-activating capabilities and one or more compounds selected from the group consisting of amino acids, peptides, and proteins that enhance the immune-activating capabilities of the aforementioned bacteria. Another type of enhancer is an enhancer for immune activation induced by bacteria with immune-activating capabilities, containing one or more compounds selected from the group consisting of amino acids, peptides, and proteins that enhance the immune-activating capabilities of the aforementioned bacteria. The enhancer of this embodiment enhances the immune activation induced by the aforementioned bacteria with immune-activating capabilities. That is, the enhancer of this embodiment enhances the immune activation compared to an immune-activating composition containing only bacteria with immune-activating capabilities.

[0157] The enhancer of one embodiment, compared to an immune-activating composition containing only bacteria with immune-activating capabilities, preferably induces interferon-α in immune cells by at least 1.01 times, 1.02 times, 1.03 times, 1.05 times, 1.08 times, 1.10 times, 1.13 times, 1.15 times, 1.18 times, 1.20 times, 1.23 times, or 1.25 times. The upper and lower limits are preferably 4.0 times or less, 3.8 times or less, 3.5 times or less, 3.3 times or less, 3.0 times or less, 2.8 times or less, 2.5 times or less, 2.3 times or less, 2.0 times or less, 1.8 times or less, or 1.50 times or less, respectively, based on the upper limit. Furthermore, these upper and lower limits can be arbitrarily combined and can be the same as the range described in the description of the bacterial immune activation enhancement effect of the compound of this embodiment.

[0158] As another specific example of an enhancer in this embodiment, the immune activation composition of this embodiment may be appropriately applied.

[0159] [Immune activation methods, methods to enhance immune activation induced by bacteria with immune-activating capabilities]

[0160] The third embodiment of this disclosure relates to an immune activation method and a method for enhancing immune activation induced by bacteria with immune-activating capabilities (hereinafter also referred to as the "enhancement method"). The immune activation method and the enhancement method include administering an immune-activating agent to a subject or ingesting an immune-activating agent into the subject, and one or more compounds selected from the group consisting of amino acids, peptides, and proteins that enhance the immune-activating capabilities of the aforementioned bacteria. The enhancement method of this embodiment enhances immune activation compared to simply administering or ingesting immune-activating bacteria.

[0161] As objects of the above method, humans and other mammals can be listed, with humans being the preferred species. Examples of mammals other than humans include mice, rats, guinea pigs, hamsters, rabbits, cats, dogs, sheep, pigs, cows, horses, goats, and monkeys.

[0162] The target can be anyone whose immunity needs to be activated. There are no special restrictions on the target, such as people who are infected with a virus, people who want to prevent viral infection, people with a cold, people who want to prevent colds, and people over 65 years of age.

[0163] Bacteria with immune-activating capabilities and one or more compounds selected from the group consisting of amino acids, peptides, and proteins that enhance the immune-activating capabilities of the aforementioned bacteria can be administered to or ingested by a subject in the form of the composition of the first embodiment described above. Generally, pharmaceutical compositions are described as "administered to a subject," and food compositions are described as "ingested by a subject." These expressions both refer to the intake of the composition into the subject's body and have the same meaning. Therefore, the two expressions are interchangeable and have no essential difference.

[0164] [Method for manufacturing the composition]

[0165] The fourth embodiment of this disclosure relates to a method for manufacturing an immune-activating composition. The manufacturing method is a method for manufacturing an immune-activating composition or an immune-activating composition with enhanced immune activation, wherein one or more compounds selected from the group consisting of amino acids, peptides, and proteins that enhance the immune activation ability of the aforementioned bacteria are added to bacteria possessing immune-activating capabilities. This immune-activating composition or immune-activating composition with enhanced immune activation is preferred from the viewpoint that the addition of the compound enhances the immune activation ability of the bacteria.

[0166] [Application of bacteria and compounds in the manufacture of compositions]

[0167] The fifth embodiment of this disclosure relates to the use of bacteria and one or more compounds selected from the group consisting of amino acids, peptides, and proteins that enhance the immune activation ability of the aforementioned bacteria in the manufacture of a composition. One application is the use of bacteria with immune activation capabilities and one or more compounds selected from the group consisting of amino acids, peptides, and proteins that enhance the immune activation ability of the aforementioned bacteria in the manufacture of an immune-activating composition. Another application is the use of one or more compounds selected from the group consisting of amino acids, peptides, and proteins that enhance the immune activation ability of the aforementioned bacteria in the manufacture of a composition for immune activation induced by bacteria with immune activation capabilities. Yet another application is the use of one or more compounds selected from the group consisting of amino acids, peptides, and proteins that enhance the immune activation ability of the aforementioned bacteria in the manufacture of an immune-activating composition for combined administration or combined uptake with bacteria with immune activation capabilities. A further application is the use of bacteria with immune activation capabilities in the manufacture of an immune-activating composition for combined administration or combined uptake with one or more compounds selected from the group consisting of amino acids, peptides, and proteins that enhance the immune activation ability of bacteria with immune activation capabilities. The specific manner of the immune activation composition, bacteria, and compound in this embodiment is as described above.

[0168] [Compounds used in the application]

[0169] The sixth embodiment of this disclosure relates to one or more compounds selected from the group consisting of amino acids, peptides, and proteins that have the immune-activating capacity-enhancing effect of the aforementioned bacteria, for use in immune activation induced by bacteria with immune-activating capacity. The specific manner of the bacteria and compounds in this embodiment is as described above.

[0170] [Bacteria or compounds used in therapeutic methods]

[0171] The seventh embodiment of this disclosure relates to the use of bacteria or compounds in a therapeutic method for immune activation. In one embodiment, for a therapeutic method for immune activation, bacteria with immune-activating capabilities are administered or ingested in combination with one or more compounds selected from the group consisting of amino acids, peptides, and proteins that enhance the immune-activating capabilities of the bacteria. In another embodiment, for a therapeutic method for immune activation, one or more compounds selected from the group consisting of amino acids, peptides, and proteins that enhance the immune-activating capabilities of bacteria are administered or ingested in combination with the aforementioned bacteria with immune-activating capabilities. The specific methods of bacteria and compounds in this embodiment are as described above. In this disclosure, application in a "therapeutic" method means application when treating the body of a subject. Application in a therapeutic method of this disclosure can, for example, be for the purpose of or accompanied by medical procedures. Application in a therapeutic method of this disclosure can, for example, be accompanied by a medical practitioner administering or ingesting a substance to a human or animal, or by a medical practitioner issuing an instruction to administer or ingest a substance to a human or animal. The application of this disclosure in therapeutic methods can be for therapeutic or preventative purposes, for therapeutic purposes or for preventative purposes in conjunction with the ingestion of a food composition, and for therapeutic purposes. The application of this disclosure in therapeutic methods can also be for applications to unhealthy individuals.

[0172] [Application of bacteria or compounds in non-therapeutic methods]

[0173] The eighth embodiment of this disclosure relates to the use of bacteria or compounds in non-therapeutic methods for immune activation. In one embodiment, the use of bacteria with immune-activating capabilities in a non-therapeutic method for immune activation involves administration or ingestion in combination with one or more compounds selected from the group consisting of amino acids, peptides, and proteins that enhance the immune-activating capabilities of the aforementioned bacteria. In another embodiment, the use of one or more compounds selected from the group consisting of amino acids, peptides, and proteins that enhance the immune-activating capabilities of the aforementioned bacteria in a non-therapeutic method for immune activation involves administration or ingestion in combination with bacteria possessing immune-activating capabilities. The specific methods of bacteria and compounds in this embodiment are as described above. In this disclosure, "non-therapeutic" application refers to the application of a substance that is not considered an application in a therapeutic method. The application in non-therapeutic methods of this disclosure can, for example, be an application not intended for medical purposes and / or not accompanied by medical procedures. The application in non-therapeutic methods of this disclosure can, for example, be without the involvement of a medical practitioner administering or ingesting a substance to a human or animal, and / or issuing instructions to administer or ingest a substance to a human or animal. The application of this disclosure in non-therapeutic methods can be, for example, for preventive or health-enhancing purposes, such as for administration or ingestion of a pharmaceutical composition or quasi-pharmaceutical. The application of this disclosure in non-therapeutic methods can also be, for example, for use in healthy individuals.

[0174] Example

[0175] The present invention will be described in more detail below based on embodiments. However, the present invention is not limited to the following embodiments.

[0176] [Experiment 1: Study on the effect of glutathione on JCM5805-induced pDC activation and IFN-α production]

[0177] In Experiment 1, we investigated whether glutathione enhances or inhibits JCM5805-induced pDC activation and IFN-α production.

[0178] <1. Preparation of Lactic Acid Bacteria Suspension>

[0179] JCM5805 bacterial cells were inoculated into 10 mL of MRS medium (Oxoid) and cultured at 30°C for 24 hours. Then, 1 mL of the cultured lactic acid bacteria suspension was inoculated into 100 mL of MRS medium and cultured at 30°C for 24 hours. Next, the lactic acid bacteria were recovered, washed three times with sterile water, heat-sterilized at 80°C for 30 minutes, and then freeze-dried to obtain heat-killed bacterial cells. The heat-killed bacterial cells were then adjusted to a concentration of 1 mg / mL using PBS (Takara Bio Inc.) to prepare a lactic acid bacteria suspension.

[0180] <2. Adjustment of Reduced Glutathione Solution>

[0181] Reduced glutathione (Tokyo Chemical Industry Co., Ltd.: G0074) was adjusted to 4 mM and 40 mM with PBS to prepare glutathione solutions.

[0182] <3. Experimental Procedure>

[0183] The experiment was conducted according to the steps (i) to (iv) below.

[0184] (i) Bone marrow cells derived from female BALB / c mice were administered at a rate of 1 × 10⁻⁶. 6 Cell suspensions were prepared by suspending cells / mL in RPMI medium (Sigma) prepared in such a manner that each component described in (Composition of the culture medium) reaches its respective final concentration as described in (Composition of the culture medium), thereby preparing a cell suspension.

[0185] (Composition of the culture medium)

[0186] ·10% by volume FBS

[0187] 100 U / mL penicillin / streptomycin

[0188] 1mM Sodium Pyruvate

[0189] ·2.5mM HEPES

[0190] • 1% by mass of non-essential amino acids (NEAA) for MEM

[0191] 50 μM β-mercaptoethanol

[0192] 100ng / mL Flt-3L

[0193] (ii) Inoculate 1 mL of each of the prepared cell suspensions and incubate them in a CO2 incubator at 37°C and 5% CO2 for 1 week to induce pDC.

[0194] (iii) The induced bone marrow cells containing pDCs were injected at a rate of 2 × 10⁻⁶. 5 The cells were suspended at a density of 1 / mL. 200 μL of this suspension was seeded into each well of a 96-well plate, and 2 μL of the JCM5805 suspension from step 1 above was added, along with 5 μL of the glutathione solution from step 2 above (final glutathione concentration: 0.1 mM or 1.0 mM). Similarly, only glutathione solution was added to the 96-well plates seeded with pDC-containing bone marrow cells. Furthermore, only JCM5805 suspension was added to the 96-well plates seeded with pDC-containing bone marrow cells.

[0195] (iv) After 24 hours, the culture supernatant was recovered and the IFN-α concentration was determined using an IFN-α assay kit (PBL Assay Science Ltd.).

[0196] The results are shown in Figure 1 . Figure 1 This is a graph showing the evaluation results of the enhancement effect of IFN-α induced by JCM5805 on pDC. Figure 1 In this document, data for adding only JCM5805 suspension will be represented as JCM5805, data for adding only glutathione solution will be represented as GSH0.1mM or GSH1.0mM (0.1mM or 1.0mM represents the final glutathione concentration, as will be the case throughout this document), and data for adding both JCM5805 suspension and glutathione solution will be represented as JCM5805+GSH0.1mM or JCM5805+GSH1.0mM. It should be noted that... Figure 2 and Figure 3 The only difference is that the lactic acid bacteria is changed from JCM5805 to Enterobacter vesiculosus strain JCM9890 (hereinafter sometimes referred to as JCM9890) or Bifidobacterium animalis subsp. lactis strain JCM10602 (hereinafter sometimes referred to as JCM10602).

[0197] Using glutathione solution alone failed to induce IFN-α production in pDCs. However, using JCM5805 suspension alone induced IFN-α production in pDCs. When using both glutathione solution and JCM5805 suspension, the IFN-α production of pDCs induced by JCM5805 was enhanced compared to using JCM5805 suspension alone. Moreover, in this case, the IFN-α production of pDCs induced by JCM5805 was enhanced in a concentration dependent on glutathione concentration.

[0198] [Experiment 2: Study on the effect of glutathione on pDC activation and pIFN-α production induced by lactic acid bacteria and bifidobacteria]

[0199] In Experiment 2, we investigated whether glutathione enhanced or inhibited pDC activation and IFN-α production induced by lactic acid bacteria other than JCM5805.

[0200] <1. Preparation of Lactic Acid Bacteria Suspension>

[0201] Lactic acid bacteria (Enteromorpha mesenchyme strain JCM9890) were cultured under the same conditions as in Experiment 1.1 above. The lactic acid bacteria were then recovered, washed three times with sterile water, sterilized by heating at 80°C for 30 minutes, and then freeze-dried to obtain heat-killed bacterial cells. The heat-killed bacterial cells were then adjusted to a concentration of 1 mg / mL using PBS (Takara Bio Inc.) to prepare a lactic acid bacteria suspension.

[0202] <2. Preparation of Bifidobacterium suspension>

[0203] Bifidobacterium (Bifidobacterium animalis subsp. lactis JCM10602) cells were inoculated into 10 mL of GAM medium (a medium prepared by adding 1% lactose by mass to GAM broth "Nissui" (Nissui Pharmaceutical Co., Ltd.) and cultured anaerobically at 37°C for 24 hours. 1 mL of the cultured bacterial suspension was then inoculated into 100 mL of GAM medium and further cultured anaerobically at 37°C for 24 hours.

[0204] <3. Adjustment of reduced glutathione solution>

[0205] The preparation of the reduced glutathione solution was carried out using the same steps as described in section 2 of Experiment 1.

[0206] <4. Experimental Procedure>

[0207] The experiment was conducted using the same steps as described in section 3 of Experiment 1. In this experiment, solutions containing only glutathione were not used; instead, solutions containing only 2 μL of each lactic acid bacteria suspension were used as a comparison.

[0208] The results are shown in Figures 2-3 . Figure 2 A graph showing the evaluation results of the enhancement effect of pDC IFN-α induced by lactic acid bacteria (Enteromorpha vesiculosus JCM9890 strain). Figure 3 A graph shows the evaluation results of the enhancement effect of pDC IFN-α induced by Bifidobacterium (Bifidobacterium animalis subspecies JCM10602).

[0209] When using either lactic acid bacteria suspension or bifidobacteria suspension alone, IFN-α production of pDC was induced by either lactic acid bacteria or bifidobacteria. Furthermore, it was confirmed that when using glutathione solution, and in conjunction with either lactic acid bacteria suspension or bifidobacteria suspension, glutathione concentration-dependently enhanced IFN-α production of pDC induced by both lactic acid bacteria and bifidobacteria.

[0210] [Experiment 3: Study on the effects of amino acids, peptides, or proteins on JCM5805-induced pDC activation and IFN-α production]

[0211] Using amino acids, peptides, or proteins instead of glutathione, the same experiment as in Experiment 1 was conducted to investigate the enhancing or inhibiting effects on IFN-α production induced by JCM5805 in pDCs. The relative values ​​of IFN-α production when using JCM5805 suspension alone (assuming 1) and the coexistence of each substance are summarized in the table below. The concentrations of each substance in the table refer to final concentrations.

[0212] All amino acids used are products from Fujifilm and Koichi Chemical. Silk peptides use "Brain Memory Essence" manufactured by Chuo Pharmaceutical Co., Ltd. of Japan; sardine-derived peptides use "Pepitate α-1000N" manufactured by Senmi Ecos; casein decomposition products use "CE90GMM" manufactured by Shinyaku Co., Ltd. of Japan; chicken collagen peptides use "C-LAP" manufactured by Japanese ham; imidazole dipeptides use "Imida peptide" manufactured by Preventive Medicine Co., Ltd. of Japan; L-cysteine ​​uses "L-cysteine ​​Kyowa" manufactured by Kyowa Fermentation Bio; enzyme-decomposed wheat protein uses "Meripro 500" manufactured by Koyo Shokai; whey protein decomposition products use "LE80GF-US" manufactured by Shinyaku Co., Ltd. of Japan; whey peptides use "Whey Peptide HW-3" manufactured by Snow Brand Milk Industry Co., Ltd.; elastin uses "Pure Ellaschin" manufactured by Vitalis Applied Research Institute; and milk protein uses "PROGEL800" manufactured by Shinyaku Co., Ltd. of Japan.

[0213] [Table 1]

[0214] Table 1: Amino acids at 500 μg / mL

[0215] (Of which, L-cysteine ​​10 μg / mL)

[0216] [Table 2]

[0217] Table 2: Peptides and Proteins at 10 μg / mL

[0218] [Table 3]

[0219] None of the substances, when used alone, induced IFN-α production in pDC. It was confirmed that glycine, L-methionine, and milk protein inhibited IFN-α production in pDC induced by JCM5805, while substances other than glycine, L-methionine, and milk protein enhanced IFN-α production in pDC induced by JCM5805.

[0220] [Experiment 4: Study on the effects of amino acids on JCM5805-induced pDC activation and IFN-α production]

[0221] In subsequent experiments, CAL-1 cells (accession number FERM BP-10914) were used as pDCs to investigate whether amino acids enhanced or inhibited JCM5805-induced pDC activation and IFN-α production. The aforementioned CAL-1 cells (accession number FERM BP-10914) were a sample kindly provided by Nagasaki University (hereinafter referred to as this sample) (all rights to this sample belong to Nagasaki University, and a license to use this sample has been obtained from Nagasaki University). Cell culture was conducted at 37°C and 5% CO2. The basal medium used for culturing CAL-1 cells and for experiments using CAL-1 cells was a medium prepared by adding 1.0% (v / v) of penicillin / streptomycin (Gibco, 15140-12) to RPMI-1640 medium (Sigma, R8758) (hereinafter also referred to as "serum-free medium").

[0222] <1. Preparation of Lactic Acid Bacteria Suspension>

[0223] The preparation of the lactic acid bacteria suspension was carried out using the same steps as described in section 2 of Experiment 1.

[0224] <2. Adjustment of Amino Acid Solution>

[0225] All amino acids used were products from Fujifilm and Koichi Pharmaceutical, diluted with PBS to 50 mg / mL.

[0226] <3. Experimental Procedure>

[0227] Prepare a serum-free culture medium containing 5.0 × 10⁻⁶ cells / mL. 5 Cell suspension of CAL-1 cells / mL was prepared by seeding 10 mL of the cell suspension into 10 cm diameter culture dishes and incubating for 16 hours (pretreatment step). CAL-1 cells were then recovered by pipetting. The recovered CAL-1 cells were then incubated at 2.0 × 10⁶ cells / mL. 5 The cells were resuspended in serum-free medium at a concentration of 1 cell / mL and seeded at 200 μL / well in each well of a 96-well microplate. Then, 2 μL of the JCM5805 suspension from step 1 above and 2 μL of the amino acid solution from step 2 above were added to each well. Similarly, only the amino acid solution was added to the 96-well plates seeded with CAL-1 cells. Then, only the JCM5805 suspension was added to the 96-well plates seeded with CAL-1 cells. After 24 hours, the culture supernatant was recovered, and the IFN-α concentration in the culture supernatant was determined using an ELISA assay with a human IFN-α multi-subtype ELISA kit (PBL Assay Science).

[0228] The relative values ​​of IFN-α production when the JCM5805 suspension is used alone (assuming a production of 1) and when all substances coexist are summarized in the following table.

[0229] [Table 4]

[0230] Table 4: Amino acids at 500 μg / mL

[0231] Except for glycine, all are L-type.

[0232] Neither substance, when used alone, induced IFN-α production in pDC. It was confirmed that glycine inhibited IFN-α production in pDC induced by JCM5805, while substances other than glycine enhanced IFN-α production in pDC induced by JCM5805.

[0233] [Experiment 5: Study on the effect of glutathione on JCM5805-induced pDC activation and IFN-α production]

[0234] In Experiment 5, CAL-1 cells (accession number FERM BP-10914) were used as pDCs to investigate whether glutathione or DL-butyrosine-(S,R)-sulfonylimine (hereinafter referred to as BSO) enhanced or inhibited JCM5805-induced pDC activation and IFN-α production. BSO is an amino acid analog that functions as an inhibitor of γ-glutamylcysteine ​​synthase and has the effect of reducing intracellular glutathione concentration. The aforementioned CAL-1 cells (accession number FERM BP-10914) were a sample kindly donated by Nagasaki University (hereinafter referred to as this sample) (all rights to this sample belong to Nagasaki University, and a license to use this sample has been obtained from Nagasaki University). Cell culture was conducted at 37°C and 5% CO2. The basal medium used for culturing CAL-1 cells and for experiments using CAL-1 cells is a medium prepared by adding 1.0% (v / v) of penicillin / streptomycin (Gibco, 15140-12) to RPMI-1640 medium (Sigma, R8758) to a final concentration (hereinafter also referred to as "serum-free medium").

[0235] <1. Preparation of Lactic Acid Bacteria Suspension>

[0236] The preparation of the lactic acid bacteria suspension was carried out using the same steps as described in section 2 of Experiment 1.

[0237] <2. Adjustment of glutathione solution>

[0238] All glutathione used was a product of Kyowa Fermentation Biotech Co., Ltd., diluted to 10mM with PBS.

[0239] <3. Adjustment of BSO solution>

[0240] All BSO was produced using Sigma (B2640) products, diluted to 40 mM with PBS.

[0241] <4. Adjustment of N-ethylmorpholine solution>

[0242] N-ethylmorpholine (Fujifilm Wako Pure Chemical Industries, 055-02113) (hereinafter referred to as NEM) was diluted to 50 mM with ultrapure water and adjusted to pH 8.0 with 1 M hydrochloric acid (Wako Pure Chemical Industries, 083-01095).

[0243] <5. Adjustment of monobromodiamine solution>

[0244] Add 500 μL of acetonitrile (Nakalaitesk, 00430-83) to dissolve monobromodiamine (Tokyo Kasei, B4220) (hereinafter referred to as mBBr), and then dilute to 8 mM with the 50 mM NEM adjusted in step 4 above.

[0245] <6. Experimental Procedure>

[0246] Prepare a serum-free culture medium containing 3.7 × 10⁻⁶ cells / mL. 5 For the CAL-1 cell suspension at 10 mL / well, the BSO 0.25 mM group was treated with 62.5 μL / well of the BSO solution mentioned in step 3 above, followed by seeding 10 mL / well into 10 cm diameter culture dishes and incubating for 16 hours. The BSO-free group received no BSO, was seeded with the same concentration of cell suspension and incubated for the same time (pretreatment step). CAL-1 cells were recovered by pipetting. The recovered CAL-1 cells were then cultured at 4.0 × 10⁶ cells / well. 5The cells were resuspended in serum-free medium at a concentration of 100 μL / well and seeded into each well of a 96-well microplate. Then, 5 μL of the JCM5805 suspension from step 1 and 5 μL of the glutathione solution from step 2 were added to each well. Similarly, only the glutathione solution was added to the 96-well plates seeded with CAL-1 cells. After 24 hours, the culture supernatant was recovered, and the IFN-α concentration was determined using an ELISA kit (PBL Assay Science). The 96-well plates were washed with PBS, and 100 μL / well of the NEM solution from step 4 and the mBBr solution from step 5 were added. The plates were incubated in the dark at room temperature for 10 minutes. 10 μL of trichloroacetic acid was added, and the supernatant was recovered after centrifugation. The solution was passed through a 0.20 μm filter (ADVATEC, 13HP020AN05), and the glutathione concentration was determined by HPLC (apparatus: HITACHI chromaster, column: Nakaraitesk COSMOSIL Packed Column 5C18-MS-2 4.6 mm I.D. × 100 mm).

[0247] The relative values ​​of glutathione concentration in CAL-1 cells with no JCM5805, glutathione, and BSO added (set to 1) are summarized in the table below.

[0248] [Table 5]

[0249] The relative values ​​of IFN-α production when JCM5805 suspension is used alone (assuming 1) and when JCM5805 suspension is used in combination with glutathione are summarized in the table below.

[0250] [Table 6]

[0251] The relative values ​​of IFN-α production when using JCM5805 suspension alone as 1 and IFN-α production when using glutathione alone are summarized in the table below.

[0252] [Table 7]

[0253] The addition of 0.25 mM BSO decreased the glutathione concentration in CAL-1 cells. Conversely, the addition of 0.25 mM glutathione confirmed that the glutathione concentration in CAL-1 cells increased to the same level as when BSO was not added.

[0254] Compared to the absence of BSO, the addition of JCM5805 reduced IFN-α production in CAL-1 cells. Conversely, the addition of 0.25 mM glutathione increased IFN-α production in CAL-1 cells. Furthermore, in the BSO-free group, the addition of glutathione increased IFN-α production in CAL-1 cells. It should be noted that glutathione alone did not induce IFN-α production.

[0255] The results above show that glutathione alone has no effect on IFN-α production in CAL-1 cells. However, combining JCM5805 and glutathione synergistically increases IFN-α production in CAL-1 cells. Furthermore, when the intracellular glutathione concentration in CAL-1 cells is altered by adding BSO, which reduces the intracellular glutathione concentration, the amount of IFN-α produced by CAL-1 cells also decreases with the decrease in intracellular glutathione concentration. This indicates that intracellular glutathione concentration is important for IFN-α production.

[0256] [Experiment 6: Study on the effects of amino acids, peptides, or proteins on pDC activation and IFN-α production induced by various lactic acid bacteria or bifidobacteria]

[0257] In Experiment 6, we investigated whether amino acids, peptides, or proteins would enhance pDC activation and IFN-α production induced by lactic acid bacteria or bifidobacteria other than JCM5805.

[0258] <1. Preparation of Lactic Acid Bacteria Suspension>

[0259] *Lactococcus curvularia* JCM1096, *Lactococcus lactis* subsp. *lactocopherol* ATCC7962, and *Lactobacillus plantarum* JCM1149 were inoculated into 10 mL of MRS medium (Becton Dickinson and Company) and cultured at 30°C for 24 hours. Then, 1 mL of the cultured lactic acid bacteria was inoculated into 100 mL of MRS medium and cultured at 30°C for 24 hours. Next, the lactic acid bacteria were recovered, washed three times with sterile water, heat-sterilized at 80°C for 30 minutes, and then freeze-dried to obtain heat-killed bacterial cells. The heat-killed bacterial cells were then adjusted to a concentration of 1 mg / mL using PBS (Takara Bio Inc.) to prepare a lactic acid bacteria suspension.

[0260] <2. Preparation of Bifidobacterium suspension>

[0261] Bifidobacterium animalis subsp. lactis JCM10602 was inoculated into 10 mL MRS medium and cultured at 30°C for 24 hours. Then, 1 mL of the cultured Bifidobacterium lactis cells was inoculated into 100 mL MRS medium and cultured at 30°C for 24 hours. Next, the Bifidobacterium lactis was recovered, washed three times with sterile water, sterilized by heat treatment at 80°C for 30 minutes, and then freeze-dried to obtain heat-killed cells. The heat-killed cells were then adjusted to a concentration of 1 mg / mL using PBS (Takara Bio Inc.) to prepare a Bifidobacterium lactis suspension.

[0262] <3. Preparation of amino acid, peptide, or protein solutions>

[0263] All amino acids used were products from Fujifilm and Koichi Chemical. Glutathione was a product from Tokyo Chemical Industry. These were prepared to 50 mg / mL concentrations using PBS.

[0264] <4. Experimental Procedure>

[0265] The experiment was conducted according to the steps (i) to (iv) below.

[0266] (i) Bone marrow cells derived from female BALB / c mice were administered at a rate of 1 × 10⁻⁶. 6 Cell suspensions were prepared by suspending cells / mL in RPMI medium (Sigma) prepared in such a manner that each component described in (Composition of the culture medium) reaches its respective final concentration as described in (Composition of the culture medium), thereby preparing a cell suspension.

[0267] (Composition of the culture medium)

[0268] ·10% by volume FBS

[0269] 100 U / mL penicillin / streptomycin

[0270] 1mM Sodium Pyruvate

[0271] ·2.5mM HEPES

[0272] • 1% by mass of non-essential amino acids (NEAA) for MEM

[0273] 50 μM β-mercaptoethanol

[0274] 100ng / mL Flt-3L

[0275] (ii) Inoculate 1 mL of each of the prepared cell suspensions and incubate them in a CO2 incubator at 37°C and 5% CO2 for 1 week to induce pDC.

[0276] (iii) The induced bone marrow cells containing pDCs were injected at a rate of 2 × 10⁻⁶. 5 The cells were suspended at a concentration of 1 / mL. 200 μL of this suspension was inoculated into each well of a 96-well plate, and 2 μL of either the lactic acid bacteria suspension from step 1 or the bifidobacteria suspension from step 2 were added. Simultaneously, 2 μL of either the amino acid or peptide solution from step 3 (final concentration: 0.5 mg / mL) was added. Similarly, only the lactic acid bacteria suspension or bifidobacteria suspension was added to the 96-well plates inoculated with pDC-containing bone marrow cells.

[0277] (iv) After 24 hours, the culture supernatant was recovered and the IFN-α concentration was determined using an IFN-α assay kit (PBL Assay Science Ltd.).

[0278] <5. Results>

[0279] The relative values ​​of IFN-α production when using suspensions of various lactic acid bacteria or bifidobacteria alone, with each suspension valued at 1, and when using a combination of various lactic acid bacteria or bifidobacteria with amino acids are summarized in the table below.

[0280]

[0281] The above results confirm that the enhanced production of alanine, asparagine, cysteine, histidine, ornithine, and glutathione by pDC induced by various lactic acid bacteria and bifidobacteria is due to IFN-α production.

Claims

1. An immune-activating composition comprising: Bacteria with immune-activating capabilities; and One or more compounds selected from the group consisting of amino acids, peptides, and proteins that enhance the immune activation capacity of the bacteria.

2. The immune-activating composition according to claim 1, wherein, The bacteria with immune-activating capabilities are lactic acid bacteria and / or acetic acid bacteria.

3. The immune-activating composition according to claim 2, wherein, The lactic acid bacteria are selected from one or more of the following: Lactococcus, Weissella, Bifidobacterium, and Lactobacillus.

4. The immune-activating composition according to claim 3, wherein, The *Lactococcus* species are either *Lactococcus lactis* subsp. *lactis* or *Lactococcus curvatus*, the *Weissella* species are *Weissella paramesenteroides*, the *Bifidobacterium* species are *Bifidobacterium animalis* subsp. *lactis*, and the *Lactobacillus* species are *Lactobacillus paraplantarum*.

5. The immune-activating composition according to claim 1, wherein, The content of the immune-activating bacteria is 0.001% by mass or more and less than 100% by mass relative to the total amount of the immune-activating composition.

6. The immune activation composition according to claim 1, wherein, The content of the compound is 0.000001% by mass or more and 90.0% by mass or less relative to the total amount of the immune activation composition.

7. The immune-activating composition according to claim 1, wherein, The ratio of the content (mass%) of the bacteria with immune-activating ability to the content (mass%) of the compound (content of one or more compounds selected from the group consisting of amino acids, peptides and proteins) / (content of bacteria with immune-activating ability) is more than 0.001 and less than 50,000.

8. The immune activation composition according to any one of claims 1 to 7, wherein, The immune activation ability refers to the ability to induce the production of interferon-α in immune cells.

9. The composition for immune activation according to claim 8, wherein, The immune cells are plasmacytoid dendritic cells.

10. The immune activation composition according to any one of claims 1 to 7, wherein, The immune activation enhancement effect is an effect that enhances the immune activation ability by more than 1.10 times.

11. The immune-activating composition according to claim 8, wherein, The compound is one or more compounds selected from the group consisting of alanine, asparagine, cysteine, glutamine, leucine, proline, threonine, tryptophan, valine, arginine, histidine, lysine, isoleucine, serine, ornithine, cystine, glutathione, imidazole dipeptide, silk peptide, sardine-derived peptide, casein breakdown product, collagen peptide, wheat protein breakdown product, whey protein breakdown product, and elastin.

12. The immune-activating composition according to claim 8, wherein, The compound is glutathione.

13. An immune activation method, comprising: The administration of a drug to a subject or the ingestion of an immune-activating bacterium by the subject, and one or more compounds selected from the group consisting of amino acids, peptides and proteins that enhance the immune-activating ability of said bacteria.

14. A method for enhancing immune activation induced by bacteria with immune-activating capabilities, comprising: The administration of a drug to a subject or the ingestion of an immune-activating bacterium by the subject, and one or more compounds selected from the group consisting of amino acids, peptides and proteins that enhance the immune-activating ability of said bacteria.

15. The method according to claim 13 or 14, wherein, The immune activation ability refers to the ability to induce the production of interferon-α in immune cells.

16. An enhancer of immune activation induced by bacteria with immune-activating capabilities, comprising one or more compounds selected from the group consisting of amino acids, peptides, and proteins that enhance the immune activation capabilities of bacteria with immune-activating capabilities.

17. The reinforcing agent according to claim 16, wherein, The immune activation ability refers to the ability to induce the production of interferon-α in immune cells.

Citation Information

Patent Citations

  • New human plasmacytoid dendritic cell line

    JP2007044008A

  • Lactic acid bacterium immunopotentiative action reinforcement composition and lactic acid bacterium immunopotentiative action reinforcement method

    JP2016005452A

  • Methods for enhancing immunostimulating activity of lactic acid bacteria

    JP2017085975A

  • Laminated glazing assembly including antenna assembly

    JP2024068171A

  • Interferon production-inducing agent containing lactic acid bacteria

    WO2012091081A1